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ABSTRACT
ENVIRONMENTAL REGULATION OF CARDIOVASCULAR DISEASE RISK AND
REGENERATIVE CAPACITY
Natasha Krystal DeJarnett
April 11, 2013
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in
the U.S., and its prevalence is predicted to increase through 2030. Acute and chronic
exposure to fine particulate matter (PM2.5) and traffic pollution is positively associated
with cardiovascular morbidity and mortality. It has been recently shown that exposure to
elevated levels of combustion pollutants including tobacco smoke and PM2.5 is associated
with decreased circulating levels of vascular progenitor cells (VPCs), angiogenic cells
that participate in vascular repair and regeneration. Several investigators have reported
that decreased VPC levels is associated with an increase in CVD risk and endothelial
dysfunction (a decrease in vasodilatation), which is a key feature in atherosclerosis.
Nevertheless, the mechanisms by which combustion pollutants affect VPC levels remains
unclear, and the contribution of pollutant-induced VPC depletion to elevated CVD risk
has not been assessed. This dissertation investigates how exposure to environmental
pollution is associated with VPC levels in a population with increased CVD risk.
The first chapter assesses 15 phenotypically distinct VPC populations with
different angiogenic potential to describe the association between VPC levels and CVD
risk factors, the Framingham Risk Score (FRS), and markers of thrombosis (fibrinogen
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and platelet mononuclear cell aggregates) and inflammation (high sensitivity C-reactive
protein (hsCRP)). The second chapter describes the association between acrolein
exposure (a combustion pollutant) and VPC levels, a novel assessment in human subjects.
To understand the vascular effects of exposure to traffic pollution, the association
between roadway proximity and VPC levels was evaluated in the third chapter. Together,
these investigations suggest that VPCs may be a mechanistic link between CVD risk and
environmental exposures. Results from these investigations may drive future mechanistic
explorations, as well as targeted diagnostic examinations and prevention interventions.
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OVERALL BACKGROUND
Public Health Burden
Cardiovascular disease (CVD) is a class of non-infectious diseases of the
circulatory system, affecting the heart or blood vessels 1. Some CVD conditions include
myocardial infarction, stroke, and heart failure. CVD is the top cause of death both
globally and in the U.S. 1, 2. The U.S. CVD prevalence in adults ≥ 20 years of age was
35.3% in 2010 1. From 2007–2009, Kentucky was ranked seventh highest in the nation
for CVD mortality, with a rate of 281.2 per 100,000, exceeding the U.S. mortality rate of
243.9 per 100,000 population 1. In 2009, 32.3% of deaths were attributed to CVD,
representing nearly 1 in every 3 deaths. Between 1999 and 2009, an average of 2,150
people in the U.S. died daily from CVD (1 death per every 40 seconds) 1. Coronary artery
disease (CAD; disease affecting the vessels that supply the heart) is the top cause of CVD
mortality, responsible for 45% of CVD deaths 3. Though CVD mortality rates have
declined in recent decades, the burden of CVD remains high. In addition to the heavy
public health burden of CVD, it also carries a substantial economic burden. The total
estimated cost of CVD in the U.S. for 2009 was $312.6 billion in direct and indirect costs
(much greater, by comparison, than the $228 billion for cancer costs in 2008) 1. The
national health and economic burden of CVD drives interest in CVD prevention.
Although CVD burden is high, most CVD conditions are preventable through
lifestyle choices including diet, physical activity, and cigarette smoking. Results from the
Nurses’ Health Study cohort indicated that 82% of coronary events were attributed to
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modifiable CVD risk factors, including proper diet and body weight, regular physical
activity, abstaining from smoking, and moderate alcohol consumption; but only 3% of
study subjects were considered low risk among all of those factors 4. Additionally, it is
estimated that 63% of heart attacks and 31% of strokes could be prevented by eliminating
modifiable risk factors 5. This emphasizes the need to investigate modifiable risk factors
for CVD development to identify opportunities for prevention.
Risk Factors
Non-modifiable risk factors for CVD are ethnicity, gender, age, and heredity.
African Americans have higher CVD mortality rates than Caucasians, and men have
higher death rates from CVD than women. In 2009 the age-adjusted CVD mortality rates
were 387.0 per 100,000 population for African American males, 281.4 per 100,000
population for Caucasian males, 267.9 per 100,000 population for African American
females, and 190.4 per 100,000 population for Caucasian females 1. As age increases,
CVD incidence and mortality risk increase. As much as 83% of CAD mortality occurs at
or above the age of 65 years 6. It has been estimated that persons with a first-degree
relative (parent, sibling, or child) that had a heart attack before age 55 in men and 65 in
women have about a 2-fold increased risk of cardiovascular events 7.
Traditional independent, modifiable risk factors for CVD include age, gender,
hypertension (high blood pressure), hypercholesterolemia (high blood cholesterol),
diabetes mellitus, and cigarette smoking 8. Hypertension increases CVD risk because
narrowed blood vessels cause the heart to work harder to pump blood to the body 9. Nine
out of 10 people 40 years or older with hypertension are expected to develop CVD in
their lifetime 8, 10. People with hypercholesterolemia, total blood cholesterol levels of
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240mg or greater, have a 2-fold increased risk of heart attack, and that risk grows to 4fold with cholesterol levels of 300mg or greater 11. It is estimated that a 10% populationwide reduction in blood cholesterol would result in a 30% decrease in CAD incidence 12.
Diabetes mellitus is associated with a 2– to 3– times higher risk for developing CAD 13.
Cigarette smokers have been reported to be 2–4 times more likely to develop CAD than
nonsmokers 14. Additionally, among people who had ever smoked cigarettes, 58%
reported having 3 or more circulatory diseases 15.
Additional risk factors include physical inactivity and obesity. Physical inactivity
is estimated to contribute toward 12.2% of the global burden of myocardial infarctions 16.
Additionally, physical inactivity has been shown to double the risk of developing CAD
17

. Physical inactivity also contributes to overweight and obese conditions. People who

are overweight or obese are believed to be more at risk for CVD because weight
increases cause the heart to work harder delivering oxygen-rich blood to the body 11.
Overweight men (body mass index ((BMI) ≥ 25) with CVD have been found to be more
at risk for CVD mortality than normal weight (BMI ≤ 25) men with CVD 18. Overweight
status in men and women has been associated with increased age-adjusted relative risks
for CVD of 1.21 and 1.20, respectively 19. Additionally, being overweight is associated
with population attributable risks of 23% (men) and 15% (women) for CAD 19. Nine to
13% of total CVD mortality has been attributed to obesity (BMI ≥ 30) 20.
The Framingham Risk Score (FRS) is a risk algorithm created from a longitudinal
study in Framingham, MA, calculated using the traditional CVD risk factors including
age, gender, hypertension, cholesterol, smoking, and diabetes. The FRS is commonly
used in clinical practice to predict patients’ risk of future adverse CAD – myocardial
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infarction or cardiac mortality 21. The FRS only predicts CAD events, not other
conditions including stroke and heart failure. Criticism of the FRS suggests that the score
is less accurate for predicting risk in women and populations with intermediate FRS
levels (FRS 10–20) 22. The FRS only assesses people who do not have CAD, primary
preventive individuals. To account for the secondary prevention population, the risk score
can be dichotomized into low FRS (FRS >20) or high FRS (FRS ≥ 20 or confirmed
CAD) categories.
Vascular Progenitor Cells
Emerging evidence suggests that vascular progenitor cell (VPC) populations are a
sensitive indicator of cardiovascular health. VPCs are circulating progenitor cells with
angiogenic properties 23, 24. They have been referenced in the literature under many
names, including circulating angiogenic progenitors, peripheral blood mononuclear cells,
and circulating progenitors from the bone marrow. Much of the research to support their
role in the vasculature focuses on a subpopulation of VPCs, endothelial progenitor cells
(EPCs). EPCs are mobilized from the bone marrow into peripheral blood circulation
through endogenous factors (including cytokines, hormones, and growth factors) and
exogenous factors (including statin use, exercise, injury, ischemia, and tumors) 25.
Following mobilization, EPCs are found lining the endothelium. The endothelium
mediates coagulation, vasodilatation, thrombosis and thromboresistance, smooth muscle
cell proliferation, and muscle wall inflammation. EPCs are necessary for upkeep and
repair of the endothelium 26 by participating in revascularization including angiogenesis
(new vessel formation from pre-existing vessels) and vasculogenesis (de novo vessel
formation) 25. Decreased EPC levels are associated with endothelial dysfunction, which is
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a hallmark of atherosclerosis development and a key mechanism in myocardial infarction
27

. Cigarette smoking, hypertension, hypercholesterolemia, diabetes, obesity, CAD, and

congestive heart failure are all associated with endothelial dysfunction 28. In humans,
exposure to combustion pollutants is associated with vasoconstriction 29. In mice,
combustion pollutant exposure is associated with decreased endothelial-mediated
vasodilatation 29. Thus, EPC levels are reduced in populations with CVD. EPC levels are
also reduced in healthy people populations exposed to combustion pollutants 30.
Air Pollution and CVD
There is growing evidence that air pollution exposure should be considered a
modifiable risk factor for CVD. In 2004, the American Heart Association issued its first
scientific statement regarding CVD risk and particulate matter exposure 31, and in 2010,
they issued another scientific statement with a much larger body of work highlighting
that exposure to fine particulate matter is a modifiable risk factor for CVD 32. Air
pollution has been found to trigger CVD events and increase CVD severity. Associations
between fine particulate matter, aerosolized particles with an aerodynamic diameter of
2.5 µm or less (PM2.5), and CVD have been defined both spatially and temporally. A 10
μg/m3 increase in PM2.5 concentration has been associated with a 4.5% increased risk of
ischemic heart disease events in short term exposure 33. An interquartile range increase in
PM2.5 over long term exposure has been associated with a 16% increased odds of acute
myocardial infarction (95% confidence interval (CI): 1.04–1.29) 34. Exposure to trafficgenerated air pollution has been associated with an odds ratio of 2.92 (95% CI: 2.22–
3.83) for a nonfatal myocardial infarction 35 and 2.54 (95% CI: 1.96–3.29) for myocardial
infarction mortality 36. People living closer to a major roadway or highway, a common
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measure used to indicate traffic exposure, have been reported to be at higher risk for
CAD mortality (relative risk 1.29, 95% CI: 1.18–1.41) 37. Living closer to a road has also
been associated with increased cardiovascular mortality following a myocardial
infarction, suggesting that people who have experienced a cardiovascular event may be
more susceptible 38. Compared with people living 200m or more from a major roadway,
odds ratios for coronary artery calcification were 1.63 (95% CI: 1.14–2.33) for
individuals living 50m or less from a major roadway and 1.34 (95% CI: 1.00–1.79) for
individuals living between 50m and 100m from a major roadway 39. This suggests an
association between roadway traffic exposure and vascular outcomes.
Mechanisms of PM2.5 Toxicity
It is well-understood that PM2.5 can be inhaled and adversely affects the
respiratory system, but research indicates that it also affects the vascular and
cardiovascular systems. There are three biological pathways by which PM2.5 exposure
may contribute to heart disease. First, the presence of PM2.5 in the lung bronchioles elicits
pulmonary oxidative stress and inflammation. This results in increased cellular
inflammatory responses including: increased cytokine levels; increased activation of
white blood cells and platelets; increased inflammatory markers (C-reactive protein
(CRP)); and increased thrombosis factors (fibrinogen). Ultimately this systemic oxidative
stress and inflammation leads to endothelial cell dysfunction (functional impairment of
the cells that line blood vessels), vasoconstriction (constriction of the blood vessels), and
progression of atherosclerosis. In the second pathway, the presence of PM2.5 in the
bronchioles causes activation of the lung autonomic nervous system (ANS) reflex arcs.
This causes an imbalance in the ANS where the sympathetic nervous system (SNS; fight-
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or-flight response) response is increased, and the parasympathetic nervous system
(PSNS; resting state) response is inhibited. Outcomes include increases in
vasoconstriction, blood pressure, platelet aggregation, heart rate, endothelial dysfunction
(an imbalance between vasoconstriction and vasodilation), and systemic oxidative stress
and inflammation. In the final pathway, PM2.5 in the bronchioles may lead to
translocation of PM2.5 or its constituents (ultrafine particulates, soluble metals, or organic
compounds) into circulating blood. This may cause vasoconstriction, endothelial
dysfunction, increased blood pressure, and systemic oxidative stress and inflammation.
Each of these three pathways suggest that the cardiovascular effects of particulate matter
exposure may be mediated by vascular effects of environmental exposures 31, 32, 40, 41 , 42.
Acrolein
Acrolein (2-propenal) is a combustion air pollutant associated with tobacco
smoke, vehicular exhaust, open fires, and industrial emissions. Acrolein is a highly
reactive electrophilic compound found in air, soil, and water, but it rapidly evaporates
from soil and water, with a half-life in the environment of approximately 1 day 43. People
are also exposed to acrolein through foods, including beer, cheese, bread, and fried food
44

, and acrolein is formed endogenously through biochemical processes of lipid

peroxidation. Targets for acrolein toxicity include the hematological, ocular, respiratory,
and cardiovascular systems 43. Acrolein metabolism in the body results in the formation
of 15 detectable products. About 20–30% of acrolein is excreted through feces (none of
the individual metabolites are excreted through the feces in significant quantities), while
60–70% of acrolein is excreted through urine 45. Hydroxypropylmercapturic acid
(HPMA) is the acrolein metabolite found in highest quantity in the urine and is only

7

produced by acrolein metabolism 46. Acrolein undergoes conjugation with glutathione,
cleavage of the γ-glutamic acid and glycine residues, n-acetylation of the cysteine to form
S-(3-oxyproply)-N-acetylcysteine (OPMA), and reduction of OPMA to form HPMA 47.
Acrolein poses a high risk for cardiovascular toxicity. Acrolein exposure is
associated with increased CVD risk, including hypertension, atherogenesis, decreased
plaque stability, suppression of cardiac flow, thrombosis, and cardiac contractility 48.
Acrolein exposure in mice is associated with dyslipidemia, decreased VPC levels, and
endothelial dysfunction 49-51. Additionally, protein-acrolein adducts have been found in
atherosclerotic lesions in the vessels of mice exposed to acrolein 51. In human endothelial
cells, acrolein can form protein adducts and oxidize thioredoxins, which promotes
atherogenesis 48, but its effects on human VPCs are unknown.
In addition to being a source of acrolein exposure, cigarette smoking increases
risk of hypertension and atherosclerosis. Moreover, chronic smoke exposure is associated
with decreased EPC levels 52. It is predicted that 50–70ppm of acrolein is generated in
tobacco smoke, compared to 6–8ppm generated by automobile exhaust from gasoline and
diesel engines 51, 53. Smoke exposure can be empirically measured by determining
metabolite levels. Nicotine, a metabolite of tobacco smoke, has a shorter in vivo half-life
than cotinine, a nicotine metabolite, with an in vivo half-life of 2–3 hours for nicotine in
blood, compared to 15–19 hours for cotinine 54. Cotinine can be measured in urine,
saliva, and serum for acute exposures, and can be measured in hair to assess chronic
exposure. Cotinine is detectable in the system for up to 7 days.
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Summary
The current study addresses an important problem: CVD is the primary cause of
morbidity and mortality and is associated with high economic burden. This research
investigates how environmental exposures may contribute to CVD risk. The results of
this investigation will expand scientific knowledge by exploring the association of VPCs
with CVD and acrolein’s primary metabolite. Theoretically, this association could
become an example and guide for future understanding of CVD risk consequences in
combustion pollutant exposure. Understanding the association between acrolein exposure
and CVD susceptibility will be important for future CVD prevention intervention policies
and mitigation of environmental risks, which may ultimately reduce the environmental
burden associated with CVD.
The current study investigates the association between environmental pollution
exposure and VPC levels. Chapter 1 presents an investigation of the relationship between
circulating VPC counts and CVD risk. Chapter 2 examines the relationship between
circulating VPC counts and HPMA, an acrolein metabolite. Chapter 3 explores the
relationship between circulating VPC counts and residential proximity to roadways.
Results of this investigation build support for the association between VPCs and CVD
risk and environmental exposures. The scientific knowledge attained by defining these
associations has the potential to drive future mechanistic pathway explorations, impact
pollution prevention interventions, and guide therapeutic interventions in the field of
environmental cardiology.
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OVERALL METHODS
The following is a listing of methods common to each chapter. Methods that are
specific to each chapter are included in the methods section of the respective chapter.
Please note that the populations are slightly different in each chapter depending on the
outcome variable measures and missing data.
Study Population
To test the research hypothesis, 240 adults undergoing primary or secondary
preventive treatment for CVD at the University of Louisville Hospital and/or Clinic
System were recruited between October 2009 and March 2011. All study consent forms
and research protocols were approved through the Institutional Review Board at the
University of Louisville (IRB 09.0174).
Inclusion criteria: Eligible individuals were (1) 18 years of age or older at the
time of enrollment; and (2) patients of the University of Louisville Hospital and/or Clinic
System requiring primary or secondary prevention for cardiovascular disease (see the
Case Definition section below).
Exclusion criteria: (1) Persons unwilling or unable to provide informed consent;
(2) subjects with significant and/or severe co-morbidities including the following
conditions: significant chronic lung, liver, kidney, hematological, or neoplastic disease;
chronic neurological or psychiatric illness; chronic infectious disease such as HIV or
hepatitis; severe coagulopathies; drug/substance abuse; and chronic cachexia; (3)
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pregnant women; and (4) prisoners and other vulnerable populations were excluded from
the current study.
Patients who met the enrollment criteria answered a brief questionnaire to obtain
demographic information, address, CVD history, tobacco smoke exposure, alcohol
intake, physical activity, and baseline clinical characteristics.
Case Definition
Primary prevention. In the current study, primary prevention cases were defined
as individuals with heart disease risk factors, including hypertension,
hypercholesterolemia, obesity, and diabetes that require management, but who had no
evident coronary artery disease (CAD). Therefore, primary prevention patients had
cardiac risk factors, but no CAD.
Secondary prevention. Secondary prevention cases were defined as individuals
with heart disease risk factors that required management/treatment and had evident heart
disease. That is, secondary prevention patients had a clinical manifestation of CAD and
were undergoing modification of risk factors. As such, in the current study, the absence
or presence of CAD determined whether a patient was defined as primary or secondary.
Questionnaire
All participants in the study were administered an interview questionnaire to
determine their medical and familial history of CVD. The questionnaire, which was
created by a cardiologist, was descriptive and asked questions regarding their
demographic information; residential address; smoking status and history; secondhand
smoke exposure; alcohol consumption; physical activity status; medication usage; and
CVD history including heart attack, heart failure, angina; hypertension,
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hypercholesterolemia, diabetes, stroke, revascularization, arrhythmia, peripheral artery
disease, aortic aneurism, and bleeding disorders. Medical records were reviewed to verify
addresses, medication history, and to provide the blood pressure reading at the time of
visit.
Risk Factor Definitions
Patients were asked if they had been told by a doctor that they had CVD risk
factors or conditions. Hypertension was defined as systolic blood pressure ≥ 140 mmHg
or diastolic blood pressure ≥ 90 mmHg. Diabetes mellitus includes glycosylated
hemoglobin test (hbA1C) results ≥ 6.5%, fasting plasma glucose levels ≥ 126 mg/dL,
and/or oral glucose tolerance test blood glucose levels ≥ 200 mg/dL. Hyperlipidemia was
defined as having total cholesterol of 240 mg/dL or above, high-density lipoprotein
(HDL) levels less than 40 mg/dL for men or less than 50 mg/dL for women, low-density
lipoprotein of 160 mg/dL or greater, and/or triglyceride levels of 200 mg/dL or more.1
Biological Sample Collection and Processing
Biological samples (urine, blood) were obtained from each participant. Urine
collected at the time of the visit was used to measure the levels of urine acrolein and
nicotine metabolites. Blood sampling was performed by a licensed phlebotomist or nurse
by venipuncture. Approximately 8 mL of blood was collected in a Vacutainer® CPT
Mononuclear Cell Preparation Tube (Becton Dickinson) for VPC analysis, 2.6 mL in a
Vacutainer® ACD tube for platelet mononuclear cell aggregate analysis, 6 mL in a
Vacutainer® Serum Tube for high-sensitivity C-reactive protein analysis, and 6 mL in a
Vacutainer® K2 EDTA (plasma) Tube for fibrinogen analysis.
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VPC Quantification
Human VPCs were identified by f

-

flow

cytometry following the methods first described by Duda et al. 55 and modified by
O’Toole et al. 30. Within 24 hours of the blood draw, blood was separated in the CPT
mononuclear separator tube by centrifugation at 2750 rpm for 30 minutes. Mononuclear
cells were separated from serum by centrifugation at 1500 rpm for 10 min. The pelleted
cells were then washed twice with 2% FBS in PBS and then incubated with 2%FBS/PBS
and FcR Blocking Reagent (Miltenyi Biotec) for 10 minutes. on ice in the dark. The cells
were incubated in the dark for 30 minutes. on ice with a panel of fluorescentlyconjugated antibodies including: PE-labeled anti-CD34 (Becton Dickinson), APClabeled anti-AC133 (Miltenyi Biotec), PE-Cy5.5-labeled anti-CD14 (Abcam), APCAlexaFluor 750-labeled anti-CD45 (Invitrogen), PE-Cy7-labeled anti-CD16 (Becton
Dickinson), FITC-labeled anti-CD31 (Becton Dickinson), anti-CD41a (Becton
Dickinson) and anti-CD235a (Becton Dickinson), Pacific Blue (Pacific Blue monoclonal
antibody labeling kit; Invitrogen), and a marker for dead cells (LIVE/DEAD fixable dead
cell stain; Invitrogen). The cells were then pelleted and washed once in 2%FBS/PBS.
Finally, the cells were resuspended in 1% FACS formaldehyde 30.
Following cell resuspension, 500,000 events were collected using the LSR II flow
cytometer (Becton Dickinson). Positive/negative boundaries for all gating was
accomplished using unstained controls. The lymphocyte population was selected in the
initial gating scheme by measuring the population that was negative for CD235a, CD41a,
and the dead cell marker (all stained with pacific blue). From that population, the CD14
and CD16 negative population were selected. Cells positive for both CD34+ (stem cells)
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and CD31+ (endothelial cells) were selected for the final population. Additionally, VPCs
were subdivided into monocytic/non-monocytic (CD45+/dim) and early/mature progenitors
(AC133+/–). FlowJo software was used to analyze the collected events. VPC counts were
normalized to the sample volume used in analysis 30. The gating scheme is shown in
Figure 1.
Platelet Mononuclear Cell Aggregate Identification
Peripheral blood was collected in an ACD tube. One mL of blood was fixed with
1.3 mL of 4% paraformaldehyde and diluted with 3 mL of deionized water for a
minimum of 30 minutes. on ice. Red blood cells were lysed with the addition of 24 mL of
water. The sample was centrifuged for 10 minutes. at 400g, and the pelleted cells were
resuspended with 1 mL of Tyrode’s buffer. The Tyrode’s-resuspended cells were divided
into 2 equal aliquots. Both aliquots were incubated on ice with FcR Blocking Reagent
(Miltenyi Biotec) for 5 minutes. The first aliquot of the platelet-mononuclear cells was
then incubated with the following antibodies for 30 minutes. on ice: FITC-labeled anti
CD41a (Becton Dickinson) and PerCP-Cy5.5-labeled anti-CD45 (Becton Dickinson).
The second aliquot was labeled with isotype control antibodies and incubated on ice for
30 minutes. Following incubation, both aliquots were washed and resuspended in
Tyrode’s Buffer. Using FACS flow cytometry, platelet mononuclear cell aggregates were
counted as events that were labeled FITC (CD41+) and PerCP-CY5.5 (CD45+) and were
calculated as a percentage of total events 30.
Cotinine Quantification
Cotinine was measured in urine using gas chromatography / mass spectrometry
(GC/MS) following the methods described by Man et al. Urine in quantities of 1 mL for
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self-reported current non-smokers or 0.25 mL for self-reported current smokers (diluted
with 0.75 mL of deionized water) was pipetted into Teflon vials. Either 0.2 nmoles (nonsmokers) or 0.5 nmoles (smokers) of the internal standard of D-3 cotinine in 0.175 mL of
methanol was added. This was followed by the addition of 0.05 mL of 0.1M NaOH and
0.325 mL of chloroform. This mixture was vortexed for 1 min. and then centrifuged at
13000 rpm for 4 minutes. After discarding the aqueous layer, 100 mg of sodium sulphate
was added to remove any excess water, briefly mixed, and the solution was allowed to sit
at room temperature for 1 minute. The clear organic extract was transferred to a gas
chromatography vial and 0.001 mL was injected to the gas chromatographer. Ions used to
monitor cotinine were 176 (cotinine) and 179 (D-3 cotinine) 56.
High Sensitivity C-Reactive Protein Quantification
The quantitative measurement of high sensitivity C-reactive protein (hsCRP) in
serum is performed using the VITROS Chemistry Products hsCRP Reagent in
conjunction with the VITROS Chemistry Products Calibrator Kit 17 and VITROS
Chemistry Products FS Calibrator 1 on VITROS 5,1 FS Chemistry Systems. Samples,
calibrators, and controls are mixed with Reagent 1 containing a buffer. Addition of antiCRP antibodies coupled to latex microparticles (Reagent 2) produces an
immunochemical reaction yielding CRP antigen/antibody complexes. The turbidity is
measured spectrophotometrically at 660 nm. Once a calibration has been performed for
each reagent lot, the CRP concentration in each unknown sample can be determined
using the stored calibration curve and the measured absorbance obtained in the assay of
the sample. Values from hsCRP were divided into three groups for low (< 1.0 mg/L),
intermediate (1.0-2.9 mg/L), and high (≥3 mg/L) levels 57.
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Fibrinogen Quantification
The STA Fibrinogen kit is intended for the quantitative determination of
fibrinogen in plasma by the Clauss clotting method 58. In the presence of excess
thrombin, the clotting time of diluted plasma is inversely proportional to the level of
plasma fibrinogen. The clot is detected by the STA-Compact, a fully automated
coagulation instrument that uses an electromagnetic mechanical clot detection system.
The oscillation of a steel ball within the cuvette containing thrombin and diluted plasma
is monitored by the STA-Compact. When the oscillation of the steel ball is stopped by
clot formation, the sensor registers the time in seconds. The time is read from a stored
curve on the STA-Compact. The time read is translated into a fibrinogen concentration
based on the manufacturer’s standard curve from the STA-Compact.
Socioeconomic Status Determination
To determine socioeconomic status (SES), addresses were geocoded in
Geographic Information System (GIS) ArcMap 9.3 (ESRI, Redlands, CA). Data for
geocoding addresses was provided by the Louisville/Jefferson County Information
Consortium (LOJIC) composite locator in ArcGIS. SES was estimated using the proxy
variable, “median household income,” and was provided at the block group level from
the 2000 U.S. Census.
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Figures and Tables

Figure 1. Flow cytometry gating scheme for VPC populations.
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CHAPTER I:
Circulating Vascular Progenitor Cells are Associated with Cardiovascular Disease
Risk
Introduction
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality
worldwide 1. Understanding CVD risk is critical to characterizing and enhancing future
preventive approaches. Vascular progenitor cells (VPCs) are believed to be necessary for
upkeep and repair of blood vessels 26 by participating in revascularization, including
angiogenesis 23 and vasculogenesis 59-61. Reduced migratory capacity and quantity of
VPCs are associated with endothelial dysfunction 62, which is a hallmark of
atherosclerosis development 63. VPC levels have been shown to be inversely associated
with intima-media thickness, also linked with atherosclerosis 64. Cigarette smoking,
hypertension, hypercholesterolemia, diabetes, obesity, coronary artery disease (CAD),
and congestive heart failure are all associated with endothelial dysfunction 28. VPC
counts are positively associated with brachial reactivity 65, 66. Circulating VPC levels have
been suggested to reflect CVD risk, with inverse associations between VPC levels and
traditional CVD risk factors including smoking52, diabetes mellitus67, total cholesterol65,
68

, and low-density lipoprotein (LDL) cholesterol 63, 68. They have also been inversely

associated with the Framingham Risk Score (FRS) 65 69, 70. VPCs are often depleted in
populations with CVD 63, 65, 69, increased CVD severity 66, 71-73, and CVD mortality 74.
The aforementioned results have not been entirely consistent in that a number of other
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studies have observed positive associations with VPC levels and the FRS 64, smoking 66,
and found no VPC differences in hypertension, hyperlipidemia, and diabetes 74.
Discrepancies in these findings are likely because VPCs are a heterogeneous population
containing cells with different angiogenic potential, and it has not yet been determined
which specific cell types are associated with CVD risk and specific CVD risk factors. We
investigated the relationship between VPCs and CVD risk factors using antigenicallydefined VPC sub-populations with demonstrated angiogenic potential (through inhibitor
of DNA binding 1 (Id1) positive staining). Our study determined which among the 15
VPC populations, were associated with varying degrees of CVD risk in an at-risk
population.
A 7-color flow cytometry procedure was used to describe the VPC profile from
peripheral blood cells among a population with varied degrees of CVD risk. The use of
antigenic markers CD31+ (endothelial), CD34+ (stem), CD45+/dim (hematopoietic/ nonhematopoietic), and AC133+/– (early/ late stem) is novel because previous studies have
used different antigenic markers to define VPCs, some of which were not specific to
VPCs including, 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate
labeled acetylated low-density lipoprotein (DiI-Ac-LDL) and lectin. Previous human
studies have also assessed cells after growth in culture, a measure indicating cellular
growth capacity and function – rather than the number of cells in circulation. This has
resulted in mixed findings in terms of the association between VPCs and CVD risk
factors.
In summary, several studies have suggested that circulating VPC levels are
decreased in populations with CVD; however, these studies used cellular definitions that

19

were not specific to VPCs. We evaluated the relationship between CVD risk and VPC
levels using antigentically defined VPCs with demonstrated angiogenic potential. We
hypothesize that VPC levels are inversely associated with CVD risk. Fifteen VPC
populations measured from peripheral blood using VPC-specific antigenic markers were
quantified using flow cytometry.
Methods
Study Population
See Overall Methods (Study Population).
Case Definition
See Overall Methods (Case Definition).
Questionnaire
See Overall Methods (Questionnaire).
Biological Sample Collection and Processing
See Overall Methods (Biological Sample Collection and Processing).
VPC Quantification
VPC populations in blood were characterized using a 7-color flow cytometry
procedure using established markers: CD31+, CD34+, CD45+/dim, and AC133+. This
method was first described by Duda et al. to define circulating endothelial cell (CEC) and
circulating progenitor cell (CPC) populations in human peripheral blood 55. Additionally,
O’Toole et al. used modifications of this model to determine human VPC populations
using the aforementioned 4 antigenic markers 30. We expanded the number of cell
populations from 6 to 15 (see Table 1). See Overall Methods (VPC Quantification).
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Selected VPC populations were also assessed for the transcription factor inhibitor
of DNA binding 1 (Id1), an antigenic marker for endothelial progenitor cells. Murine
studies suggest that this marker indicates endothelial progenitor cell activity; when Id1+
cells are suppressed from the bone marrow in trans-genic mice, angiogenesis is impaired
in tumors, and circulating endothelial progenitor cell levels in circulation are depleted 7577

. The current study used modifications of the Wheat et al. protocol for Id1

determination 51. White blood cells isolated from human blood of healthy volunteers
(University of Louisville IRB 11.0432) were sorted for selected subsets by f

-

, permeabilized (0.1 % Triton X-100/ phosphate buffered
saline (PBS), room temperature, 3 minutes), blocked (1 % bovine serum albumin
(BSA)/PBS, room temperature, 15 minutes) and incubated over night with the primary
antibody against Id1 (proteintech, Chicago, Il; 1:250) at 4°C. After incubation with the
fluorescence labeled secondary antibody (1:500, 1 hour, room temperature; anti-rabbit488, Invitrogen, Carlsbad, CA), cells were mounted with DAPI containing mounting
media (Invitrogen, Carlsbad, CA) and images were taken by fluorescence microscopy
(EVOSfl, AMG, Hill Creek, WA).
Platelet Mononuclear Cell Aggregate Identification
Platelet mononuclear cell aggregates were identified using flow cytometry
following the procedures described in O’Toole et al. Using flow cytometry, platelet
mononuclear cell aggregates were counted as events that were FITC (CD41+) and PerCPCY5.5 (CD45+) and were calculated as a percentage of total events 30. See Overall
Methods (Platelet Mononuclear Cell Aggregate Identification).
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Statistical Analysis
Influence of CVD Risk on VPCs, Thrombosis and Inflammation
Independent samples t-tests (Wilcoxon methods when appropriate) were used to
test for differences (association) in mean VPC values, thrombosis markers (fibrinogen
and platelet mononuclear cell aggregates), and inflammation markers (hsCRP), between
those in the low Framingham Risk Score (FRS) category (FRS ≤ 20) and high FRS
category (FRS ≥ 20 or established CVD). Additionally, t-test techniques were used to
compare these variables among people with a low number of risk factors (< 2 CVD risk
factors among age ≥ 40 years, male gender, hypertension, diabetes, hyperlipidemia,
diabetes, and current smoking) and a higher number of risk factors (≥ 2 CVD risk
factors). This more crude comparison was utilized to determine if individuals with a
small number of risk factors in the study population were different from the remaining
population or if the use of this crude variable provided additional information or
understanding in addition to the FRS t-test comparisons. The VPC levels assessed were
log transformed for normality, consistent with previous literature 74. VPC values
presented are the VPC counts normalized to sample volume for consistency.
Additionally, population demographics and CVD risk factors were compared
among tertiles of low, medium, and high log-transformed VPC levels for a VPC
population positively associated with the FRS category and a population inversely
associated with the FRS category. Tertiles were defined by dividing the population’s
VPC levels into cut points for 3 evenly distributed groups. Demographics and CVD risk
factors were compared using χ-squared analysis for categorical variables and analysis of
variance (ANOVA) for continuous variables.
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Simple linear regression modeling techniques were used to test for associations
between VPC and the FRS category (unadjusted). Generalized Linear Modeling (GLM)
techniques examined whether FRS category was independently associated with VPC
levels, adjusting for, ethnicity, whether they consumed alcohol, body mass index (BMI)
and, socioeconomic status (SES; median household income at the block group level).
GLM techniques are appropriate for variables that are not normally distributed. The
VPCs followed a gamma distribution rather than a normal distribution; therefore, the
GLMs with each VPC entered as the dependent variable utilized the gamma probability
distribution and the log link function. Traditional model fit statistics (log-likelihood) were
used to develop the most parsimonious model. In addition we tested whether higher order
modeling (e.g., exponential, cubic) improved model fit using traditional model-fit
statistics (AIC, log-likelihood, etc.).
Influence of Thrombosis and Inflammation on VPCs
Similar to above, simple linear regression modeling techniques were used to test
for associations between (1) VPC and thrombosis markers (fibrinogen and platelet
mononuclear cell aggregates) and (2) VPC and inflammation markers (hsCRP)
unadjusted. That is, we tested whether VPC values were associated with thrombosis
markers and/or inflammation markers, unadjusted. Also similar to above, GLM
techniques for the VPC models utilized the gamma probability distribution and the log
link function to examine whether thrombosis (fibrinogen and platelet mononuclear cell
aggregates), and inflammation markers (hsCRP) were independently associated with
VPC levels, adjusting for hypertension, hyperlipidemia, diabetes, smoking, age, ethnicity,
alcohol, gender, BMI, and SES. Traditional model fit statistics (log-likelihood) were used
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to develop the most parsimonious model. In addition we tested whether higher order
modeling (e.g., exponential, cubic) improved model fit using traditional model-fit
statistics (AIC, log-likelihood, etc.).
Note: The current study only reports/presents the models that had a significant
relationship with a VPC and the main effect of interest. Also, there was significant
overlap between many of the 15 VPC populations measured; therefore associations for
each VPC population were measured separately in individual GLMs.
Results
Participant Characteristics
The Healthy Heart Study population was 51±10 years of age; 53.6% (n=53.6)
male; 56.3% (n=103) Caucasian; 40.3% (n=73) current smokers; 82.2% (n=148)
hypertensive; 64.8% (n=116) had hypercholesterolemia; 59.6% (n=106) obese; and were
taking medications including 55.3% (n=99) angiotensin-converting-enzyme (ACE)
inhibitors, 63.7% (n=114) beta-blockers, and 52.5% (n=94) statins. Population
demographics are shown in Tables 3 and 4. Small differences between the demographics
are due to missing data attributed to log transforming VPC-levels: 0 values cannot be log
transformed and are, therefore, missing.
Id1 Staining
Id1 staining was used to determine if the isolated VPC populations were
endothelial progenitor cells. VPC-1 (CD31+/34+/45dim), VPC-2 (CD31+/34+/45+), VPC-5
(CD31+/AC133+), VPC-6 (CD31+/34+), VPC-7 (CD31+/34+/45dim/AC133–), VPC-8
(CD31+/34+/45+/AC133–), VPC-11 (AC133+), and VPC-13 (CD34+/AC133+) were
positive for Id1 (Figure 2). VPC-4 (CD31+/34+/45+/AC133+) and VPC-14
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(CD34+/45+/AC133+) had positive and negative Id1 cells (Figure 2). Id1 staining on the
remaining cell populations is pending.
CVD Risk and its association with VPCs, Thrombosis, and Inflammation
Comparisons between VPC levels, thrombosis, and inflammation were made
among the risk score levels. A number of the VPC populations and fibrinogen were
significantly different between the low and high FRS populations, Table 2. Specifically,
the high FRS population had significantly higher levels of VPC-1 (CD31+/34+/45dim;
p=0.023), VPC-3 (CD31+/34+/45dim/AC133+; p=0.008), VPC-13 (CD34+/AC133+;
p=0.020), VPC-15 (CD34+/45dim/AC133+; p=0.006), and fibrinogen (p=0.006).
Additionally, comparisons between VPC levels, thrombosis, and inflammation
were also made among the number of risk factors, Table 3. The high risk population had
≥ 2 CVD risk factors and the low risk population had < 2 CVD risk factors. None of the
VPCs, hsCRP, or fibrinogen were different between the risk factor strata, but platelet
mononuclear cell aggregates were higher in the high-risk population (p=0.040).
Demographic Comparisons among VPC-3 Tertiles
Differences between the characteristics of the populations within low, medium,
and high VPC-3 (CD31+/34+/45dim/AC133+) tertiles are shown in Table 4. VPC-3 was
selected because it is the most specific sub-population positively associated with FRS.
Participants in the high FRS category (FRS ≥ 20 or experienced a cardiovascular event)
were significantly more likely to have high VPC-3 levels (p=0.004). Lymphocyte count
was positively associated with VPC-3 levels (p<0.001). Fibrinogen was positively
associated with VPC-3 levels (p=0.003).
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Demographic Comparisons among VPC-5 Tertiles
Differences between the characteristics of the populations within low, medium,
and high VPC-5 (CD31+/AC133+) tertiles are shown in Table 5. VPC-5 was selected
because it is positively (not significant) associated with FRS in the t-test comparison;
levels in the high-FRS were more than double in the low-FRS population. Only
lymphocyte count was positively associated with VPC-5 levels (p<0.001).
Adjusted Association between FRS and Circulating VPC Levels
Significant associations between FRS category and VPC levels adjusted for
ethnicity, alcohol, body mass index (BMI), and socioeconomic status (SES; median
household income at the block group level) are shown in Table 6. FRS category was
inversely associated with VPC-5 (CD31+/AC133+; β=-0.679, p=0.003). FRS category
was positively associated with VPC-3 (CD31+/34+/45dim/AC133+; β=0.840, p<0.001),
VPC-13 (CD34+/AC133+; β=0.706, p=0.001), and VPC-15 (CD34+/45dim/AC133+;
β=0.864, p<0.001). None of the remaining covariates explored above improved model fit
and are not included in the final model.
Adjusted Associations between Thrombosis and VPC Levels
The association between VPCs and thrombosis was assessed using fibrinogen as a
marker of thrombosis (Figure 3A). The regression model adjusted for hypertension,
hyperlipidemia, diabetes, smoking, age, ethnicity, alcohol, gender, BMI, and SES (Figure
3A). VPC-1 (CD31+/34+/45dim; β=0.002, p=0.007), VPC-3 (β=0.002, p=0.004), VPC-13
(β=0.002, p=0.004), and VPC-15 (β=0.003, p=0.003) were positively associated with
fibrinogen. In addition, as seen in Figure 3B, C, D, and E, positive associations are
demonstrated in scatterplots of fibrinogen and the predicted means of the VPCs from the
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adjusted regression models for VPC-1 (R2= 0.399, p<0.001), VPC-3 (R2= 0.335,
p<0.001), VPC-13 (R2= 0.386, p<0.001), and VPC-15 (R2= 0.414, p<0.001).
The association between VPCs and thrombosis was also assessed using platelet
mononuclear cell aggregates as a marker of thrombosis. As seen in Figure 4A, there was
a positive association between VPC-6 (CD31+/34+; β= 0.040, p=0.036), VPC-9 (CD34+;
β= 0.044, p=0.026), and VPC-14 (CD34+/45+/AC133+; β= 0.118, p<0.001) and platelet
mononuclear cell aggregates (CD41+/45+) adjusted for hypertension, hyperlipidemia,
diabetes, smoking, age, ethnicity, alcohol, gender, BMI, and SES. In addition, as seen in
Figure 4B, C, and D, positive associations are demonstrated in scatterplots of platelet
mononuclear cell aggregates and the predicted means of the VPCs from the adjusted
regression models for VPC-6 (R2= 0.287, p<0.001), VPC-9 (R2= 0.315, p<0.001), and
VPC-14 (R2= 0.431, p<0.001).
Adjusted Association between Inflammation and VPC Levels
The association between VPCs and inflammation was assessed using hsCRP
levels as a marker of inflammation (Figure 5). The adjusted regression excluded the
population with hsCRP levels above 10 mg/L (n=19) due to increased likelihood of an
infection or inflammatory diseases unrelated to cardiovascular disease 78, 79. The models
were adjusted for hypertension, hyperlipidemia, diabetes, smoking, ethnicity, alcohol,
gender, BMI, and SES. VPC-5 (CD31+/AC133+) and VPC-11 (AC133+) levels were
significantly inversely associated with hsCRP levels (β= -0.076, p= 0.042) and (β= 0.078, p= 0.037). In addition, as seen in Figure 5B inverse associations are demonstrated
in a scatterplot of hsCRP and the predicted means of the VPCs from the adjusted
regression models for VPC-5 (R2= 0.032, p=0.033). The scatterplot of hsCRP and the
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predicted means of the VPCs from the adjusted regression models for VPC-11 (R2=
0.008, p=0.278) was not significant.
Discussion
We conducted a cross-sectional assessment of the association between VPC levels
and CVD risk in the Healthy Heart Study. A majority of the VPC populations assessed
were Id1+, indicating they have endothelial progenitor cell lineage. The high FRS
population had significantly higher levels of VPC-1 (CD31+/34+/45dim), VPC-3
(CD31+/34+/45dim/AC133+), VPC-13 (CD34+/AC133+), VPC-15 (CD34+/45dim/AC133+),
and fibrinogen. In the adjusted analysis of VPCs vs. CVD risk, we found that VPC-5
(CD31+/AC133+) was significantly inversely associated with the FRS category, while
VPC-3, VPC-13, and VPC-15 were positively associated with the FRS category. VPC-1,
VPC-3, VPC-13, and VPC-15 were positively associated with fibrinogen, and VPC-6,
VPC-9, and VPC-14 were positively associated with platelet mononuclear cell
aggregates. VPC-5, and VPC-11 (AC133+) were inversely associated with hsCRP, which
is associated with inflammation.
VPC levels are hypothesized to decrease as CVD risk increases and
atherosclerosis progresses 80. Multiple studies have reported an inverse association
between the number of risk factors and VPC levels 63, 81. Vasa et al. found this
association in CD34+/KDR+ cells (kinase insert domain receptor (KDR); marks for
endothelial cells) 63, and Schmidt-Lucke et al. found this association the VPC population
KDR+/CD34+/CD45dim 81. We did not find a significant association between VPCs and
the number of risk factors. It may be that our population was a rather unhealthy
population, in terms of cardiovascular health, and there are not enough people with few
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risk factors to accurately depict the association between VPCs and the number of CVD
risk factors. Future studies should include a comparison population with less than 2
Framingham risk factors.
FRS has been associated with decreased VPC levels in other investigations 65, 69,
70

. In the current study, VPC-5 significantly decreased as FRS category increased. This

suggests that the depletion of CD31+/AC133+ may be driving the inverse association with
FRS and VPC levels. Additionally, these cells were significantly associated with hsCRP,
suggesting that the association between VPC-5 and FRS may be associated with
inflammation. Furthermore, VPC-11 (AC133+) was inversely associated with FRS
category in the univariate analysis (not in the adjusted model; β=-0.406, p=0.076); but
this population was also inversely associated with hsCRP, suggesting reason to
investigate the potential role of inflammation in depletion of VPCs in the high FRS
category. More research is required to understand how risk factors potentially influence
the VPC levels, thereby contributing to risk: more specifically CVD risk factors, e.g.
hypertension, in the reduction of circulating levels of CD31+/AC133+ VPCs. A future
direction for our research involves understanding how each risk factor influences VPC
levels and incorporating a weight for each into our model. Other future directions should
involve the prognostic diagnostic utility of VPCs, particularly VPC-5, in the clinical
setting.
The current study also determined that 3 cell populations were positively
associated with the FRS category, VPC-3, VPC-13, and VPC-15. VPC-3 is a subcategory of VPC-13 and VPC-15, suggesting that VPC-3 may be driving the associations
seen through the CD31+ (endothelial) and CD45dim (non-hematopoietic) phenotypes.
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Faidini et al. described that as atherosclerosis progresses to an event in low risk
populations, VPCs are mobilized into circulation 80. This suggests that people who have
had a CVD event may have higher levels of some VPCs. Because the secondary
preventive population is included in the high FRS category, a cardiovascular event in
these individuals may have mobilized VPC-3, VPC-13, and VPC-15 into circulation.
Güven et al. reported a positive association between VPCs and coronary artery disease
severity 72. Shintani et al. demonstrated that VPCs increase following an acute
myocardial infarction (AMI), with a peak 7 days post-AMI 82. Leone et al. and Massa et
al. observed that VPC counts increase following an acute AMI by comparison to healthy
controls 83, 84. Similarly, Sobrino et al. and Yip et al. demonstrated increased VPC levels
following a stroke 85, 86. Xiao et al. also indicated a positive association between FRS and
VPC levels 64. Their investigation, however, evaluated a population with FRS ≤ 10, a low
risk population. Our population included high-risk individuals and secondary preventive
patients. Additionally, Xiao et al. investigated this association in DiI-Ac-LDL+/ lectin+
cells grown in culture, which are markers that are not highly specific to VPCs.
Furthermore, the culture assay reflects VPC growth and proliferative capacity, rather than
circulating VPC levels. A second possible explanation for the positive association
between VPCs and FRS is that as risk increases, the more likely the subjects are receiving
primary preventive treatment for CVD risk factors. Therefore, they are more likely to be
taking medications, including statins, which may increase VPC levels 64, 81, 87, 88 and VPC
mobilization 89-91. VPC-3, VPC-13, and VPC-15, however, were not associated with
statin use in the current study population. VPC-3, VPC-13, and VPC-15 were positively
associated with aspirin use, indicating that aspirin may play a role in the association.
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When the regression model was adjusted for aspirin, the association between FRS and
VPC-3, VPC-13, and VPC-15 remained positive and significant. Additionally, these cells
were positively associated with fibrinogen. This suggests that thrombosis may be driving
the positive association between FRS and VPC-3, VPC-13, and VPC-15. Moreover,
fibrinogen was significantly higher in people in the high FRS category (β=51.24,
p<0.001; adjusted for ethnicity, alcohol, BMI, and SES). Aspirin was positively
correlated with hypertension and hyperlipidemia in the current study, suggesting that
future research should assess hypertension and hyperlipidemia in association with VPC3, VPC-13, and VPC-15 levels, although there was no association revealed from the
current at-risk study population. Future directions should investigate risk factors and
medications that are positively associated with VPCs and the potential for positive
cardiovascular outcomes.
There were 2 remaining VPC populations that were inversely associated with FRS
category in the univariate analysis, VPC-7 (CD31+/34+/45dim/AC133–; β=-0.419,
p=0.036) and VPC-11 (AC133+; β=-0.609, p<0.001). VPC-7 lost significance when BMI
was entered into the model, the positive association with BMI seems to suppress the
relationship between FRS category and the VPC-7. VPC-11 lost significance when
ethnicity was entered into the model; African Americans had significantly higher levels
of VPC-11. VPC-2 (CD31+/34+/45+) and VPC-8 (CD31+/34+/45+/AC133–) were
positively associated with FRS in the univariate model, but when ethnicity was entered
into the model, both lost significance. African Americans had significantly lower levels
of VPC-2 and VPC-8. We do not report the non-significant models as discussed. While
BMI, ethnicity, and SES seem to be independently associated with some of the remaining
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VPCs and may account for the differences observed, FRS category may not account for
the differences after adjustment for these variables. Future planned manuscripts will
further explore these relationships.
We found that VPC-1, VPC-3, VPC-13, and VPC-15 levels were positively
associated with fibrinogen, suggesting a pro-thrombotic state. This association may be
driven by the CD31+ (endothelial) and CD45dim (non-hematopoietic) phenotypes.
Additionally, the current study found that VPC-6, VPC-9, and VPC-14 were positively
associated with platelet mononuclear cell aggregate levels, also suggesting a thrombotic
state. The association may be driven by the CD45+ (hematopoietic) and AC133+ (early
stem) cell phenotypes. The thrombin receptor protease activated receptors-1 (PAR-1) is
expressed on VPCs, and thrombin may activate the fibrinolytic pathway that balances
thrombosis by breaking down thrombi 92, 93. Additionally, VPCs were shown to be
recruited to resolving venous thrombi 94. This suggests that VPC levels could increase in
the presence of a thrombus. In the current study, some VPC levels were positively
associated with fibrinogen and platelet mononuclear cell aggregates, verifying this
hypothesis. Further research is needed to understand the relationship of VPCs with
thrombosis in advanced stages of CVD.
We determined that circulating levels of VPC-5 and VPC-11were inversely
associated with hsCRP in subjects with a range of CVD risk factors. Because systemic
inflammation is linked to CVD and vascular injury, this association is biologically
plausible. Previous investigations of this association have provided mixed results. Studies
that investigated the effects of hsCRP -treated VPCs in culture also demonstrated VPC
decreases defined as DiI-Ac-LDL+/lectin+ cells 95 and vascular endothelial growth factor
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receptor-2+ (VEGFR-2+, also known as KDR+) cells 96. George et al. determined that DiIAc-LDL+/ lectin+- colony forming units (CFU) were positively associated with hsCRP
levels 86. As previously mentioned, DiI-Ac-LDL and lectin are not highly specific to
VPCs, and CFUs are more indicative of the proliferative capacity of the isolated VPCs.
Additionally, inverse associations between hsCRP and VPCs have been found in
individuals with diabetes mellitus (a major risk factor for CVD) for CD34+ cells 97, 98 and
CD34+/133+ cells 97. In the current study, we did not find an association between CD34+
(VPC-9) or CD34+/AC133+ (VPC-13). Schmidt-Lucke et al. showed that circulating
VPCs, defined as CD34+/KDR+ cells, quantified using flow cytometry were not
significantly associated with hsCRP 99. Our study also found no significant association
between CD31+/34+ (VPC-6) cells and hsCRP (both KDR+ and CD31+ cells indicate
endothelial lineage and the VPC-6 population was Id1 positive, also indicating
endothelial progenitor cell lineage). Results from the current study suggest that VPC-5
and VPC-11, likely driven by the more specific sub-population VPC-5 (CD31+/AC133+),
decreased with increased markers of inflammation in adults at increased heart disease
risk. Future research should investigate the role of VPC-5 and inflammation.
Among the multiple strengths of the current investigation, we had a large
population with varying degrees and types of CVD risk. Because we were able to
measure 15 different populations of VPCs, we were able to investigate which antigenic
markers are associated with CVD risk factors. Through the thorough questionnaire and
medical records review, we were able to conduct an extensive evaluation of CVD risk
factors. Additionally, we reduced risk of misclassification and potential confounding in
self-reported smoking status by measuring cotinine levels, the primary urine metabolite
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of nicotine. Cotinine levels accounted for both smoking and environmental tobacco
smoke exposure.
Some of the limitations to the investigation involve the type of study we have
selected. Cross-sectional studies are limited in their ability to demonstrate causality, but
are useful to identify associations that can be used to generate hypotheses for future
cohort studies. Other potential limitations include the time of sample collection. Some of
the research on VPCs indicates that they demonstrate diurnal variations and should be
collected at the same point each day 64. Additionally, studies on urine metabolites suggest
that the urine sample should be collected at the first catch or first void. Recruitment
limitations include the inability to recruit a population that is representative of the
population that visits the clinics. None of the recruiting personnel fluently spoke
languages other than English; therefore, some potential participants that did not have a
translator present were not able to provide consent for the study or participate in the
interview questionnaire. In addition, based on the recruitment being entirely from
cardiology clinics, we lack a true population-based sample, we had an at-risk population.
This poses a limitation in being able to generalize the results to the entire population.
Also, our study does not account for all population variabilities that may affect VPC
levels; for example, some studies exclude pre-menopausal women because of the VPC
fluctuations that result due to menstruation 100, 101. Our study did not include a variable
for cyclic variability due to the menstruation phase of female study participants nor did
we exclude women from study, although the regression models did adjust for gender.
Future studies should include a healthy comparison population or healthy ageand sex-matched controls. Regressing VPCs against the sum of CVD risk factors will be
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more robust when including more people that have ≤ 1 CVD risk factor. Future planned
investigations will explore relationships between VPCs and ethnicities. Our population is
richly diverse with just over 40% of the population being African American, and
understanding risks and VPC levels in this population will be of added scientific benefit.
Additionally, the VPC levels should be assessed in their association with CAD severity
determined by angiography. The association between VPC levels and cardiac output,
determined through echocardiography, should also be assessed to understand the
association between VPC levels and cardiac outcomes.
In summary, these observations suggest that levels of some VPCs are associated
with increased CVD risk, a pro-thrombotic state, and inflammation. Previous research has
indicated mixed results in terms of CVD risk and VPC levels. It appears that this is
because VPCs are a heterogeneous population containing cells with varied angiogenic
potential. Additionally, some previous research employed markers that are not specific to
VPCs and assays not specific to circulating VPC levels. The inverse association between
VPCs and FRS category appears to be driven by the CD31+/AC133+ phenotype. The
positive associations between VPCs and FRS category as well as VPCs and fibrinogen
appear to be driven by the CD31+/34+/45dim/AC133+ phenotype. The positive association
between VPCs and platelet mononuclear cell aggregates appears to be driven by the
CD34+/45+/AC133+ phenotype. The inverse association between VPCs and hsCRP
appears to be driven by the CD31+/AC133+ phenotype. Future direction should assess
VPC changes in a cohort study following people forward in terms of the interaction
between VPC levels, risk factors, and disease. Determining the phenotype associated with
risk could guide future use of VPC phenotypes for diagnostic and therapeutic purposes.
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Figures and Tables

Table 1. Listing of the VPC populations identified.
n/d: not determined.
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Figure 2. Abundance of Id-1 in populations of human blood progenitor cells.
(A) Fluorescence images (original magnification 60 x) of human blood CD34+/AC133+,
CD34+/AC133–, and CD34–/AC133– cells. White blood cells were sorted by flow
cytometry and fluorescence labeled with Alexa-488-Id-1 and DAPI. Phase-contrast and
fluorescence images (left panel, original magnification 60 x) of human blood sorted for
CD31+/CD34+/CD45dim. Cells were incubated with Alexa-488 secondary antibody (only)
and DAPI. (B) Fluorescence single cell images (original magnification 60 x) of human
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blood cells sorted for VPC-11 (AC133+), VPC-5 (AC133+/CD31+), VPC-4
(AC133+/CD34+/CD31+/CD45+), VPC-14 (AC133+/CD34+/CD45+), VPC-6
(CD31+/CD34+), VPC-1 (CD31+/CD34+/CD45dim), VPC-7
(CD31+/CD34+/CD45dim/AC133–), VPC-2 (CD31+/CD34+/CD45+), and VPC-8
(CD31+/CD34+/CD45+/AC133–). Sorted cells were fluorescence labeled with Alexa-488Id-1 and DAPI and merged images of cells show colocalization of Id1 (Alexa-488-Id-1)
with the nucleus (DAPI). (C) Fluorescence images (original magnification 60 x) of
human umbilical vein endothelial cells (HUVEC) fluorescence labeled with Alexa-488Id-1 and DAPI (left image) or incubated with Alexa-488 secondary antibody (only) and
DAPI (right).

Table 2. Comparison between the low- and high- FRS risk populations.
The low FRS category has a FRS < 20. The high FRS category has a FRS ≥ 20 or has
experienced a cardiovascular event. VPC counts per µL sample. Fibrinogen units
(mg/dL). Platelet mononuclear cells are the percent total of cells CD41+/45+. HsCRP
units (mg/L). ** = significant at the 0.05 level.
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Table 3. Comparison between the low- and high- CVD risk factor populations.
The low-risk population has ≤ 1 Framingham risk factor for CVD among age ≥ 40 years,
male gender, hypertension, hyperlipidemia, diabetes, and current smoking. The high-risk
population has ≥ 2 Framingham risk factors. VPC counts per µL sample. Fibrinogen units
(mg/dL). Platelet mononuclear cells are the percent total of cells CD41+/45+. HsCRP
units (mg/L). ** = significant at the 0.05 level.
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Table 4. Demographic comparison stratified by VPC-3 tertile.
Low VPC-3 mean = -3095 ± 980.15, range = --6075 – -2030 (log-transformed VPC-3
normalized to uL sample *1000). Medium VPC-3 mean = -1452 ± 299.7, range = -2008 –
-878.5. High VPC-3 mean = -143.2 ± 532.2, range = -828.5 – 1589. Current, never, and
former smokers based on self-report. Environmental smoke is secondhand smoke
exposure in self-reported non-smokers. FRS = Framingham Risk Score. High FRS
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category has a FRS ≥ 20 or experienced a cardiovascular event. BMI = body mass index.
CABG = coronary artery bypass graft. PCI = percutaneous coronary intervention. ACE =
angiotensin-converting-enzyme. Age in years. Cotinine units (ng/mL). Fibrinogen units
(mg/dL). HsCRP units (mg/L). Vasodilators included nitrates and hydralazine. Platelet
mononuclear cells are the percent total of cells CD41+/45+. Median household income in
USD at the US Census block group level. ** = significant at the 0.05 level.
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Table 5. Demographic comparison stratified by VPC-5 tertile.
Low VPC-5 mean = -1414 ± 655.1, range = -3361 – -631.5 (log-transformed VPC-5
normalized to uL sample *1000). Medium VPC-5 mean = -233.5 ± 201.2, range = -622.3
– 68.22. High VPC-5 mean = 818.0 ± 757.8, range = 69.53 – 3968. Current, never, and
former smokers based on self-report. Environmental smoke is secondhand smoke
exposure in self-reported non-smokers. FRS = Framingham Risk Score. High FRS
category has a FRS ≥ 20 or experienced a cardiovascular event. BMI = body mass index.
CABG = coronary artery bypass graft. PCI = percutaneous coronary intervention. ACE =

43

angiotensin-converting-enzyme. Age in years. Cotinine units (ng/mL). Fibrinogen units
(mg/dL). HsCRP units (mg/L). Vasodilators included nitrates and hydralazine. Platelet
mononuclear cells are the percent total of cells CD41+/45+. Median household income in
USD at the US Census block group level. ** = significant at the 0.05 level.

Table 6. Association between VPCs and FRS Category.
The β presented is the adjusted β for the FRS Category. Models were adjusted for
ethnicity, alcohol, BMI, and SES.
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Figure 3. Adjusted association between VPCs and fibrinogen.
The β presented is the adjusted β for fibrinogen. (A) Models were adjusted for
hypertension, hyperlipidemia, diabetes, smoking, age, ethnicity, alcohol, gender, BMI,
and SES. (B) Predicted value of mean VPC-1 was calculated form the adjusted regression
model. (C) Predicted value of mean VPC-3 was calculated form the adjusted regression
model. (D) Predicted value of mean VPC-13 was calculated form the adjusted regression
model. (E) Predicted value of mean VPC-15 was calculated form the adjusted regression
model.
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Figure 4. Adjusted association between VPCs and platelet mononuclear cell
aggregates.
Platelet mononuclear cell aggregates are the percent total of cells CD41+/45+. The β
presented is the adjusted β for platelet mononuclear cell aggregates. (A) Models were
adjusted for hypertension, hyperlipidemia, diabetes, smoking, age, ethnicity, alcohol,
gender, BMI, and SES. (B) Predicted value of mean VPC-6 was calculated form the
adjusted regression model. (C) Predicted value of mean VPC-9 was calculated form the
adjusted regression model. (D) Predicted value of mean VPC-14 was calculated form the
adjusted regression model.
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Figure 5. Adjusted association between VPCs and hsCRP.
People with hsCRP > 10 were excluded from analysis (n=19). The β presented is the
adjusted β for hsCRP. (A) Models were adjusted for hypertension, hyperlipidemia,
diabetes, smoking, age, ethnicity, alcohol, gender, BMI, and SES. (B) Predicted value of
mean VPC-5 was calculated form the adjusted regression model. (C) Predicted value of
mean VPC-11 was calculated form the adjusted regression model.
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CHAPTER II
Contribution of Acrolein to Cardiovascular Disease Risk and Vascular Progenitor
Cell Levels
Introduction
Cardiovascular disease (CVD) is the leading cause of death in the U.S. 1. Vascular
progenitor cells (VPCs) are suspected to be a sensitive indicator of vascular health.
Several investigators have reported that decreased levels of circulating VPCs, cells that
participate in vascular upkeep and repair, are associated with increased CVD risk 63, 65, 69,
severity 66, 71-73, and mortality 74. Exposure to ambient air pollution, including particulate
matter, is associated with increased CVD incidence and mortality 29, prompting a
scientific statement from the American Heart Association indicating that air pollution
exposure should be considered a modifiable risk factor for CVD 32. It has been recently
shown that exposure to elevated levels of combustion pollutants, including fine
particulate matter in healthy young adults 30 and acrolein in mice 51, decrease circulating
VPC levels. Therefore, we investigated the association between acrolein and VPC levels
in humans.
Emerging evidence suggests that VPC populations may provide a mechanistic
link between combustion pollutant exposure and CVD. The endothelium mediates
vasodilatation and thrombosis. In mice, combustion pollutant exposure is associated with
decreased endothelial-mediated vasodilation 29. In humans, exposure to combustion
pollutants is associated with vasoconstriction 29, reduced brachial artery diameter 102, and
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flow mediated vasodilation 103, 104. VPCs are necessary for upkeep and repair of the
endothelium 26, participating in revascularization. Decreased VPC levels are associated
with endothelial dysfunction, a hallmark of atherosclerosis development and a key
mechanism in myocardial infarction 27. VPCs are heterogeneous populations, and
understanding which phenotypically distinct population is associated with acrolein
metabolism may be important in characterizing risk.
Acrolein exposure is ubiquitous and includes multiple sources of exposure,
including tobacco smoke, vehicular exhaust, open fires, and industrial emissions 51.
Increased acrolein exposure is associated with increased CVD risk, including
hypertension, atherogenesis, decreased plaque stability, suppression of cardiac flow,
thrombosis, and cardiac contractility 48. Acrolein exposure in mice is associated with
dyslipidemia, decreased VPC levels, and endothelial dysfunction 49-51. Additionally,
protein-acrolein adducts have been found in atherosclerotic lesions in the vessels of
acrolein-exposed mice 51. While acrolein promotes atherogenesis via protein adduct
formation and oxidation of thioredoxins in human endothelial cells,48 its effects on
human VPCs are unknown. We explored the association between VPCs and acrolein
using hydroxypropylmercapturic acid (HPMA), the acrolein metabolite found in highest
quantity in the urine, and produced only by acrolein metabolism 46. Because tobacco
smoke is a source of acrolein exposure and a risk factor for CVD, we also measured urine
cotinine, the primary nicotine metabolite, to reduce potential confounding.
Our objective was to examine the relationship between CVD risk and levels of the
acrolein metabolite, HPMA. To characterize risk, we investigated VPC levels and
markers of inflammation and thrombosis along with the Framingham Risk Score (FRS) to
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indicate clinical risk prediction – a novel assessment in the field. We hypothesized that
acrolein metabolism is inversely associated with VPC levels, thereby contributing to
CVD risk.
Methods
Study Population
See Overall Methods (Study Population).
Case Definition
See Overall Methods (Case Definition).
Questionnaire
See Overall Methods (Questionnaire).
Biological Sample Collection and Processing
See Overall Methods (Biological Sample Collection and Processing).
VPC Quantification
See Overall Methods (VPC Quantification).
Platelet Mononuclear Cell Aggregate Identification
See Overall Methods (Platelet Mononuclear Cell Aggregate Identification).
HPMA Quantification
We measured HPMA in urine using mass spectrometric analysis following the
methods described by Carmella et al. 105 and modified by Conklin et al. 46. One mL of
urine was combined with 2.5 nmol of C13 HPMA (internal standard) and added to an
Oasis Max Solid Phase Extraction column for purification. The column protocol included
sequentially applying: 6 mL MeOH, 6 ML 2% NH4OH, urine, 6 mL 2% NH4OH, and 6
mL MeOH. The column was dried with N2 and then washed with 6 mL 2% formic acid.
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Finally, it was eluted with 30% MeOH in 2% formic acid. The HPMA fraction was
lyophilized and reconstituted in 1 mL of water. The solution was then syringe filtered and
purified using high-performance liquid chromatography (HPLC). The HPMA fraction
was lyophilized and subsequently derivitized with 40 µL acetonitrile and 40 µL N,OBis(trimethylsilyl)trifluoroacetamide (BSTFA) for 1 hour at 60oC. One µL of the sample
was applied to the gas chromatography / mass spectrometry (GC/MS) (Agilent 6890N)
for quantification. The ion fragments 366 (HPMA) and 369 (C13 HPMA) were compared
for quantification. HPMA values were normalized to creatinine, which was measured in
urine using the Cobas Mira 5600 Autoanalyzer.
Cotinine Quantification
Cotinine was measured in urine using GC/MS following the methods described
by Man et al. 56. See Overall Methods (Cotinine Quantification).
Statistical Analysis
Descriptive statistics were computed to describe the Healthy Heart Study
population and are presented as n (%) for categorical variables and mean (SD) for
continuous variables. Population demographics, CVD risk factors, markers of thrombosis
(fibrinogen and platelet mononuclear cell aggregates), and markers of inflammation
(hsCRP) were compared among tertiles representing low, medium, and high HPMA
levels. The tertiles were formed by dividing the population’s HPMA levels into 3 even
cut points. Population characteristics were compared using one-way analysis of variance
(ANOVA) techniques for continuous variables and χ-squared analysis for dichotomous
or categorical variables.
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VPC levels were compared among the HPMA tertiles using ANOVA techniques.
The VPC levels assessed were log transformed for normality, consistent with previous
literature 74. VPC values presented are the VPC counts normalized to sample volume for
consistency.
To explore the relationship between HPMA and smoking, independent sample ttest techniques were used to test for bivariate associations between self-reported smoking
status and mean cotinine levels along with cotinine strata and mean HPMA levels.
Cotinine was stratified into 2 strata representing low (cotinine < 200 ng/mL) and high
(cotinine ≥ 200 ng/mL) smoking levels. These values are commonly used in the insurance
industry to distinguish non-smokers from smokers. Additionally, HPMA was regressed
against cotinine to verify the relationship between smoking and HPMA.
To explore the relationship between HPMA and CVD risk, HPMA was regressed
against the FRS. In the current database, the FRS was only determined for the primary
prevention population. As such, to include the secondary population, we divided the
entire population into 2 FRS categories. The low FRS category includes the population
with an FRS < 20, while the high FRS population includes the population with an FRS ≥
20 and the population that has experienced a cardiovascular event (i.e. the secondary
preventive population). Independent samples t-tests were also used to examine
differences in HPMA levels between the 2 FRS categories in both the whole population
and subsequently for the subset of non-smokers.
Generalized Linear Modeling (GLM) techniques were used to examine whether
the circulating VPC levels, markers of inflammation and thrombosis, and the FRS were
associated with HPMA levels; after adjusting for age, gender, ethnicity, cotinine, alcohol
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consumption, body mass index (BMI), hypertension, diabetes, diuretics, and vasodilators.
The FRS and FRS category were only adjusted for ethnicity, alcohol consumption, and
BMI (the remaining variables are included in the FRS equation). Because the VPC levels
appeared to follow a gamma distribution, GLMs that assessed VPCs as the dependent
variable utilized the gamma probability distribution and the log link function. For FRS
Category the binomial distribution was used. All other GLMs utilized the normal
probability distribution and the identity link function. Traditional model fit statistics (loglikelihood) were used to develop the most parsimonious model. In addition we tested
whether higher order modeling (e.g., exponential, cubic) improved model fit using
traditional model-fit statistics (AIC, log-likelihood, etc.). Additionally, as an exploratory
analysis, the aforementioned analysis was repeated in non-smokers to demonstrate the
association with acrolein metabolism in the absence of smoke exposure.
Results
Participant Characteristics
The sample population was middle-aged (51 years old), majority male (n=111,
52.6%), Caucasian (n=120, 56.9%) and either a current smoker (n=82, 39.2%) or former
smoker (n=71, 33.8%). A majority of the sample population had hypertension (n=168,
81.2%); hyperlipidemia (n=131, 63.6%); were obese (BMI ≥ 30, n=118, 57.6%); or using
angiotensin-converting-enzyme (ACE) inhibitors (n=112, 54.4%), beta-blockers (n=129,
62.6%), or statins (n=109, 52.9%) (Table 7).
Non-smoking Participant Characteristics
The non-smokers in the sample population were middle-aged (53 years old), a
majority male (n=68, 53.5%), Caucasian (n=73, 57.5%), and were either a former smoker
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(n=71, 55.9%) or a never smoker (n=56, 44.1%). A majority of the non-smoking sample
population had hypertension (n=103, 81.7%); hyperlipidemia (n=78, 61.4%); were obese
(BMI ≥ 30, n=74, 59.7%); or using angiotensin-converting-enzyme (ACE) inhibitors
(n=68, 55.3%), beta-blockers (n=79, 64.2%), or statins (n=64, 52.0%) (Table 8).
Demographic Comparison
Differences between the characteristics of the populations within low, medium,
and high HPMA tertiles are shown in Table 7. There were no significant differences
between HPMA tertile and gender; hypertension; hyperlipidemia; diabetes mellitus;
environmental tobacco smoke; myocardial infarction; stroke; heart failure; most
medications except diuretics; age; the FRS (in primary preventive patients); lymphocyte
count; thrombosis, inflammation, and median household income. Caucasians were more
likely to have higher HPMA than African Americans (p=0.005). Obese (BMI ≥ 30)
participants had lower HPMA (p=0.015). Smoking demonstrated highly significant
associations with HPMA; high HPMA was associated with self-report of being a current
smoker (p<0.001), inversely associated with having never smoked (p=0.001) and being a
former smoker (p<0.001), and was associated with higher cotinine levels (p<0.001).
Participants in the high FRS category (FRS ≥ 20 or experienced a cardiovascular event)
had significantly higher HPMA (p=0.006). Participants with revascularization including
coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), or stents
also had higher HPMA (p=0.040) Participants who were taking diuretics had lower
HPMA (p=0.005).
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Non-smoking Demographic Comparison
Differences between the characteristics of the non-smoking population within
low, medium, and high HPMA tertiles are shown in Table 8. Obese (BMI ≥ 30)
participants were less likely to have high HPMA (p=0.033). People with high HPMA
were more likely to self-report having never smoked (p=0.015) and less likely to be a
former smoker (p=0.015), and more likely to have higher cotinine (p<0.001). Participants
that were taking diuretics were more likely to have low HPMA (p=0.023). People with
low HPMA had a significantly a higher mean hsCRP level (p=0.004).
Association between VPCs and CVD Risk with HPMA Tertile
Results of the ANOVA comparison between HPMA tertile and VPC levels are
shown in Table 9. VPC-2 ((CD31+/34+/45+); p=0.030), and VPC-8
((CD31+/34+/45+/AC133–), p=0.035) were inversely associated with HPMA levels. When
stratified into self-reported non-smokers, none of the VPC populations were significantly
associated with HPMA tertile (Table 10).
Association between Smoking and HPMA
Associations between smoking and HPMA are illustrated in Figure 6. Mean
cotinine levels were significantly higher in smokers when compared to non-smokers
(1033.79 ± 93.84 v. 142.26 ± 37.78, p<0.001). Mean HPMA levels were significantly
higher in the population with high cotinine (<200ng/mL) than low cotinine (≥200
ng/mL), with values of 726.49 ± 74.61 and 144.93 ± 16.40 µg/g creatine (p<0.001),
respectively. Regression analysis results confirmed that HPMA levels were positively
associated with cotinine (β=0.257, R2=0.422, p<0.001).
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Association between CVD Risk and HPMA
Association between the FRS and HPMA are shown in Figure 7. A scatterplot
demonstrates that HPMA levels increase as the FRS increases in the primary prevention
population (R2=0.101, p=0.021). In a scatterplot of the primary preventive population of
non-smokers, there is no significant association between HPMA and FRS (R2=0.010,
p=0.595). The population in the low FRS category (FRS < 20) demonstrates significantly
lower HPMA than the high FRS category (FRS ≥ 20 or experienced a cardiovascular
event) with values of 181.45 ± 46.74 and 458.73 ± 30.04 µg/g creatine (p<0.001),
respectively. When stratified into the non-smoking population, although HPMA was
about half that of the total population, HPMA remained significantly higher in the high
FRS category with mean values of 105.16 ± 23.04 and 220.87 ± 26.69 µg/g creatine
(p=0.001) for the low and high FRS categories, respectively.
Adjusted Association of CVD Risk and HPMA
The adjusted GLM results of CVD risk and HPMA are shown in Table 11. The
associations were adjusted for age, gender, ethnicity, cotinine, alcohol, BMI,
hypertension, diabetes, and diuretics. VPC-2 ((CD31+/34+/45+), β=-0.002, p<0.001),
VPC-8 ((CD31+/34+/45+/AC133–), β=-0.002, p<0.001), VPC-11 ((AC133+), β=-0.001,
p=0.046), and VPC-14 ((CD34+/45+/AC133+), β=-0.002, p=0.029) were inversely
associated with HPMA. Platelet mononuclear cell aggregates (CD41+/45+) were
positively associated with HPMA (β=0.003, p=0.030). The FRS was associated with
HPMA (β=0.012, p<0.001) after adjustment for ethnicity, alcohol, and BMI (the
remaining variables are reflected in the FRS). The FRS category, also adjusted for
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ethnicity, alcohol, and BMI, demonstrated a positive association with HPMA where the
low FRS category had lower HPMA (β=-0.003, p=0.002).
Adjusted Association of CVD Risk and HPMA in Non-smokers
The adjusted GLM results of CVD risk and HPMA in non-smokers are shown in
Table 12. The associations were adjusted for age, gender, ethnicity, cotinine, alcohol,
BMI, hypertension, diabetes, and diuretics. VPC-2 ((CD31+/34+/45+), β=-0.003,
p<0.001), VPC-8 ((CD31+/34+/45+/AC133–), β=-0.003, p<0.001), VPC-9 (CD34+; β=0.001, p=0.024), and VPC-14 ((CD34+/45+/AC133+), β=-0.011, p=0.001) were inversely
associated with HPMA; however, VPC-11 ((AC133+), β<0.001, p=0.793) was no longer
associated with HPMA. Platelet mononuclear cell aggregates (CD41+/45+) were no
longer associated with HPMA (β=0.004, p=0.245). The FRS was no longer associated
with HPMA (β=0.010, p=0.097) after adjustment for ethnicity, alcohol, and BMI. The
FRS category was no longer associated with HPMA (β=-0.004, p=0.069).
Discussion
While associations between acrolein exposure and CVD risk have been shown in
mice, this is the first study to examine the association between the primary urine acrolein
metabolite, HPMA, and VPC levels as a measure of CVD risk in humans. The current
results demonstrate a significant association with HPMA and ethnicity. Obese individuals
were more likely to have low HPMA. Additionally, an inverse association between
HPMA and use of diuretics was observed. Comparison between HPMA tertiles
demonstrated that VPC-2 (CD31+/34+/45+) and VPC-8 (CD31+/34+/45+/AC133–) levels
significantly decrease as HPMA levels increase. We verified that smokers have
significantly higher HPMA levels, which was expected because cigarette smoke is a
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source of acrolein. Our results demonstrated that HPMA is positively associated with the
FRS and the FRS categories, indicating that HPMA levels significantly increase as risk
increases. This association was consistent among FRS categories in non-smokers,
suggesting that the association is not driven solely by tobacco smoke exposure. In the
fully adjusted models, we determined that HPMA was significantly inversely associated
with VPC-2, VPC-8, VPC-11 (AC133+), and VPC-14 (CD34+/45+/AC133+).
Additionally, HPMA was significantly positively associated with thrombosis (platelet
mononuclear cell aggregate levels), the FRS, and FRS categories. VPC-2, VPC-8, VPC-9
(CD34+), and VPC-14 and significantly associated with HPMA when the models
included non-smokers only.
One particularly interesting finding was that Caucasians are more likely to have
higher HPMA than African Americans in the Healthy Heart Study population. There was
not a significant difference between smoking (empirical or self-reported) and ethnicity
among the study participants. African Americans participants were also more likely to be
obese, and HPMA levels decreased as BMI increased. The likely link between HPMA
and ethnicity is diuretic use. There is a significantly higher proportion of African
Americans using diuretics compared to Caucasians in the Healthy Heart Study, and we
found that diuretic use decreased as HPMA tertile increased. There was not a significant
association between smoking and BMI, and there was no association between HPMA and
self-reported exercise. There was an association between BMI and diuretics, where obese
patients were significantly more likely to be taking diuretics. When the population using
diuretics is excluded from analysis, there is no longer a significant association between
HPMA and BMI. Therefore, our adjusted regression model included diuretics as a
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potential confounder. Future research should investigate other factors among different
ethnicities and relating to BMI that may contribute to differences in HPMA levels.
VPC-2 (CD31+/34+/45+), VPC-8 (CD31+/34+/45+/AC133–), and VPC-14
(CD34+/45+/AC133+) levels were inversely associated with HPMA in both the total
population and non-smokers. O’Toole et al. found that VPC-2 was inversely associated
with increased exposure to PM2.5 30. Because VPC-8 is a sub-population of VPC-2, it is
likely that VPC-8 is driving the association seen with VPC-2; therefore, the true
association appears to be with VPC-8 and HPMA. The VPC-8 population should be
assessed in future environmental research as a sensitive indicator of CVD risk and
combustion pollution exposure, which could potentially provide insight into
environmental mechanisms of vascular toxicity.
We found that platelet mononuclear cell aggregates were positively associated
with HPMA, suggesting that thrombosis increases as acrolein (a combustion pollutant)
exposure increases. These results were similar to the finding by O’Toole et al. that
increased combustion pollutant exposure (PM2.5) was associated with increased platelet
mononuclear cell aggregates in healthy young adults 30. Our population of middle-aged
adults with increased CVD risk demonstrated a similar association with acrolein
metabolism.
This is the first investigation to report an association between HPMA and FRS.
Because the FRS includes smoking, and smoking is a source of acrolein, we also
analyzed the association with the FRS and HPMA in non-smokers. The positive
association between HPMA and FRS category remained in the non-adjusted comparisons
in the whole population as well as the non-smoking population. This suggests that the
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association between HPMA and FRS may not be driven entirely by tobacco smoke
exposure, but also possibly by acrolein through the environment, endogenous exposure,
or in food. In the adjusted analyses, HPMA no longer remained significantly lower in the
low FRS category when assessing the whole population nor the non-smoking population.
To further understand the environmental contribution, ambient or personal monitoring of
acrolein will be necessary.
Strengths of the current study include the large study population with a wide
range of CVD risk factors, allowing us to investigate how differences in risk factors are
associated with HPMA. Additionally, our study includes multiple phenotypically
different VPC populations to understand which cell types are associated HPMA. This
expands on past VPC research by understanding differences in the phenotypes associated
with environmental exposures. The endothelial cell (CD31+), stem cell (CD34+),
hematopoietic cell (CD45+), and early and late stem cell (AC133+/ –) phenotypes
demonstrated significantly lower levels with increased HPMA concentrations. The
progenitor cell populations with the non-hematopoietic (CD45dim) cell phenotype were
not associated with acrolein metabolism, a novel finding in combustion pollution-linked
vascular research. An added benefit of our study was that we were able to account for
potential confounding by measuring cotinine levels, the primary urine nicotine
metabolite, in addition to collecting data on self-reported smoking. We adjusted for
potential confounding due to diuretic use, which was associated with ethnicity and BMI.
One potential limitation in this study is the lack of ambient acrolein
measurements. Acrolein is highly volatile, and the stationary acrolein monitors are not
widely dispersed throughout Jefferson County, KY to attain a valid estimation of
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exposure levels in our study population. An additional limitation is that investigations of
urine metabolites generally collect urine at the first catch. Our study collected urine (for
HPMA and cotinine) and blood (for VPCs and markers of inflammation and thrombosis)
at the time of the visit (between 9 am and 5 pm). Similarly, some of the research on VPCs
indicates that they demonstrate diurnal variations and recommend that blood should be
collected at the same point each day 64. Our collection of blood and urine at the same time
point did allow a snapshot of collective exposures and risk from that corresponding point
in time. Some of the limitations to the investigation involve the type of study we have
selected. Cross-sectional studies are limited in their ability to demonstrate causality, but
are useful to identify associations that can be used to generate hypotheses for future
cohort studies. Moreover, none of the recruiting personnel fluently spoke languages other
than English; therefore, some potential participants without a translator present were not
able to provide consent for the study or participate in the interview questionnaire. In
addition, based on the recruitment being entirely from cardiology clinics, we lacked a
true population-based sample, but rather an at-risk population. This poses a limitation in
being able to generalize the results to the larger community.
For future directions of this research, it would be beneficial to measure ambient
acrolein levels, in order to determine the portion of HPMA that may be attributed to
environmental exposure. Understanding the basis for the differences in HPMA among
different ethnicities and obesity will be valuable in characterizing risk. We could also
investigate other biomarkers of environmental exposures to determine how they affect
CVD risk and VPC levels. A future case-control study with controls that have no CVD
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and are non-smokers would be beneficial to better understand differences in risk and
acrolein metabolite levels.
In summary, these findings suggest that increased HPMA levels are associated
with increased CVD risk. The major finding in the current study is that acrolein
metabolism appears to be associated with vascular injury, as reflected by reduced VPC
levels. This is accompanied by increased CVD risk and thrombosis. VPC-2 and VPC-8
levels were significantly lower with increased HPMA levels. Because VPC-8 is a subpopulation of VPC-2, it is likely that VPC-8 (specifically the AC133– late stem cell
phenotype) is driving the association. Additionally, VPC-11 and VPC-14 were inversely
associated with HPMA. A marker of thrombosis was significantly higher with increased
HPMA. Lastly, as the FRS increased, HPMA levels increased. The associations seen in
VPC-2, VPC-8, VPC-9, and VPC-14 were associated among the non-smoking
population, suggesting that environmental exposure to acrolein poses additional
endothelial risk that is detectable through these VPC populations.
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Figures and Tables

Table 7. Demographic comparison stratified by HPMA tertile.
Low HPMA mean = 54.89 ± 17.76, range = 19.11-87.29 μg/g creatinine. Medium HPMA
mean = 202.50 ± 100.37, range = 87.81 – 405.23 μg/g creatinine. High HPMA mean =
940.12 ± 693.73, range = 424.03 – 4908.19 μg/g creatinine. Current, never, and former
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smokers based on self-report. Environmental smoke is secondhand smoke exposure in
self-reported non-smokers. BMI = body mass index. FRS = Framingham Risk Score.
High FRS category has a FRS ≥ 20 or experienced a cardiovascular event. CABG =
coronary artery bypass graft. PCI = percutaneous coronary intervention. ACE =
angiotensin-converting-enzyme. Age in years. Cotinine units (ng/mL). Fibrinogen units
(mg/dL). HsCRP units (mg/L). Vasodilators included nitrates and hydralazine. Platelet
mononuclear cells are the percent total of cells CD41+/45+. Median household income in
USD at the US Census block group level. ** = significant at the 0.05 level.
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Table 8. Demographic comparison stratified by HPMA tertile in non-smokers.
Low HPMA mean = 54.89 ± 17.76, range = 19.11-87.29 μg/g creatinine. Medium HPMA
mean = 202.50 ± 100.37, range = 87.81 – 405.23 μg/g creatinine. High HPMA mean =
940.12 ± 693.73, range = 424.03 – 4908.19 μg/g creatinine. Current, never, and former
smokers based on self-report. Environmental smoke is secondhand smoke exposure in
self-reported non-smokers. BMI = body mass index. FRS = Framingham Risk Score.
High FRS category has a FRS ≥ 20 or experienced a cardiovascular event. CABG =
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coronary artery bypass graft. PCI = percutaneous coronary intervention. ACE =
angiotensin-converting-enzyme. Age in years. Cotinine units (ng/mL). Fibrinogen units
(mg/dL). HsCRP units (mg/L). Vasodilators included nitrates and hydralazine. Platelet
mononuclear cells are the percent total of cells CD41+/45+. Median household income in
USD at the US Census block group level. ** = significant at the 0.05 level.

Table 9. Comparison of VPC levels among HPMA tertiles.
VPC counts per µL sample. ** = significant at the 0.05 level.
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Table 10. Comparison of VPC levels among HPMA tertiles in non-smokers.
VPC counts per µL sample. ** = significant at the 0.05 level.

67

Figure 6. Association between HPMA and smoking.
(A) Mean cotinine for self-reported non-smokers was 145.26 ± 37.78 and 1033.79 ±
93.84 ng/mL for smokers. (B) Mean HPMA levels for low (<200 ng/mL) and high (≥200
ng/mL) cotinine strata were 144.93 ± 16.40 and 726.49 ± 74.61 ug/g creatinine,
respectively. (C) HPMA regressed against cotinine levels.
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Figure 7. Association between HPMA and the FRS.
A) Scatterplot of HPMA and FRS. (B) Scatterplot of HPMA and FRS in self-reported
non-smokers. (C) Mean HPMA levels for low (FRS < 20) and high (FRS ≥ 20) or
experienced a cardiovascular event FRS category were 181.45 ± 46.74 and 453.73 ±
30.04 μg/g creatinine, respectively. (D) Mean HPMA levels for low and high FRS
categories in self-reported non-smokers were 105.16 ± 23.04 and 220.87 ± 26.69 μg/g
creatinine, respectively.
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Table 11. Adjusted association between HPMA and CVD Risk.
Models were adjusted for age, gender, ethnicity, cotinine, alcohol, BMI, hypertension,
diabetes, and diuretics. FRS = Framingham Risk Score. GLMs that assessed VPCs as the
dependent variable utilized the gamma probability distribution and the log link function.
GLMs for platelet mononuclear cell aggregates and the FRS were assessed using normal
probability distribution and the identity link function. The GLM for FRS category was
analyzed using the binomial distribution. The FRS and FRS Category were only adjusted
for ethnicity, alcohol, and BMI.

Table 12. Adjusted association between HPMA and CVD Risk in non-smokers.
Models were adjusted for age, gender, ethnicity, cotinine, alcohol, BMI, hypertension,
diabetes, and diuretics in self-reported non-smokers. FRS = Framingham Risk Score.
GLMs that assessed VPCs as the dependent variable utilized the gamma probability
distribution and the log link function. GLMs for platelet mononuclear cell aggregates and
the FRS were assessed using normal probability distribution and the identity link
function. The GLM for FRS category was analyzed using the binomial distribution. The
FRS and FRS Category were only adjusted for ethnicity, alcohol, and BMI.
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CHAPTER III
The Association of Residential Proximity to Roadway with Circulating Vascular
Progenitor Cell Levels
Introduction
Cardiovascular disease (CVD) is the top cause of death in the United States,
responsible for 1 in every 3 deaths 1. Vascular progenitor cells (VPCs) are suspected to be
a sensitive indicator of vascular health. Several investigators have reported that decreased
levels of circulating VPCs, cells that participate in vascular upkeep and repair, are
inversely associated with increased CVD risk 63, 65, 69, severity 66, 71-73, and mortality 74.
Growing evidence of the associations between particulate matter exposure and CVD risk
led to a scientific statement from the American Heart Association indicating that air
pollution exposure should be considered a modifiable risk factor for CVD 32. It has been
recently shown that exposure to elevated levels of vehicular exhaust pollutants, including
fine particulate matter in healthy young adults 30 and acrolein in mice 51, were associated
with decreased circulating VPC levels. Therefore, the association between traffic
pollution exposure and VPC levels should be explored, particularly in a susceptible
population of adults at increased risk for CVD.
Traffic emissions include a mixture of particulate, gaseous, and volatile
pollutants. It is assumed that people living closer to major roadways bear more exposure
to these emissions. Epidemiological research indicates that living in close proximity to a
major roadway, a common measure used to indicate traffic pollution exposure, is
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associated with increased risk of CVD and CVD mortality. Close proximity to roadways
has been associated with increased coronary heart disease mortality 37, 106, 107, myocardial
infarction 38, 108, heart failure 109, deep vein thrombosis 110, and stroke mortality 111. Creactive protein (CRP), a clinical risk indicator, is positively associated with traffic
density 112. In addition, inverse associations have been determined between roadway
proximity and sub-clinical risk including coronary artery calcification 39 and oxidized
low-density lipoprotein (LDL) 113. Investigation of the association between traffic
pollution exposure and vascular outcomes at the cellular level may provide a greater
understanding of the environment’s role in cardiovascular disease risk.
Multiple studies have confirmed that traffic pollutants decrease in quantity as
distance to roadway increases. Roorda-Knape et al. demonstrated that black smoke and
NO2 background levels are reached at 300m of a roadway carrying a mean of 80,000152,000 vehicles/day 114. Zhu et al. 2002 reported that CO and particulate matter (PM)
background concentrations were reached at 150m of a freeway with a mean of 13,900
vehicles/hour 115. A meta-analysis determined that background concentrations are reached
at 100–400m for PM, 200–500m for NO2, and 100–300m for ultrafine particulate matter
(UPM) from mobile sources 116. Studies finding associations between roadway proximity
and adverse cardiovascular outcomes generally consider people to be exposed within:
100m of a limited-access highway or multilane highway 108; 300m of an interstate, state
highway, or major arterial 106; and 50m of major arterial and 100m of an interstate or
state highway 117. Our investigation provides a missing link in by examining associations
within close proximity to a major roadway that carries a moderate mean number of
vehicles per day (5000). We consider people within 50m of the roadway to be exposed.
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While a substantial body of research has established that living in close proximity
to a major roadway is associated with increased CVD morbidity and mortality, the impact
of exposure to traffic pollution on VPC levels has not been assessed. Our objective was to
investigate the association between residential proximity to a roadway and VPC levels as
a measure of CVD risk. We hypothesized that residential proximity to roadway is
associated with VPC levels in a population at increased risk for CVD. Residential
addresses were geocoded to determine distance to roadway in a population of individuals
at increased risk for CVD. VPC levels for 15 different antigenically-defined VPC
populations were measured by flow cytometry to determine associations with residential
proximity to a major roadway. This investigation evaluated the established association
between roadway proximity and CVD risk through investigation of VPC levels, a novel
assessment.
Methods
Study Population
See Overall Methods (Study Population).
Case Definition
See Overall Methods (Case Definition).
Questionnaire
See Overall Methods (Questionnaire).
Biological Sample Collection and Processing
See Overall Methods (Biological Sample Collection and Processing).
VPC Quantification
See Overall Methods (VPC Quantification).
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Platelet Mononuclear Cell Aggregate Identification
See Overall Methods (Platelet Mononuclear Cell Aggregate Identification).
Residential Proximity to Roadway
Residential addresses of study participants were provided during the patient
interview questionnaire or through the review of medical records. Distance to roadway
measurements were carried out using Geographic Information System (GIS) ArcMap 9.3
(ESRI, Redlands, CA). Data for geocoding addresses was provided by the
Louisville/Jefferson County Information Consortium (LOJIC) composite locator in
ArcGIS. Subject addresses were first examined for flaws including spelling errors,
invalid characters, and invalid format, etc. Addresses that could not be geocoded were
cross-referenced with other known addresses, or attempts were made to manually place
the points. The records were examined for duplicates, which were most often apartments,
condominiums, and mobile home communities. We examined aerial imagery and
excluded records where the geocoded point was not at the residential location; many of
these were mobile home communities or postal office boxes. Road vehicle counts were
provided by the Kentucky Transportation Cabinet. Major roadway was defined as a road
carrying an annual mean of 5,000 or more vehicles/day. Roadway proximity was entered
into the statistical model as dichotomous data indicating living within 50m of a major
roadway. Socioeconomic status (SES), estimated using the proxy variable “median
household income,” was provided at the block group level from the 2000 U.S. Census.
“Residential duration”, which indicates the length of time the home was owned by the
current owner, was also included in the model. These housing records were available
through the Jefferson County, KY Property Valuation Administrator via LOJIC. The final
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model only included the population that had a residential duration at their current home
of at least 6 months.
PM2.5 Estimation
Fine particulate matter (particulate matter with an aerodynamic diameter less than
2.5μm; PM2.5) levels are collected hourly at 5 ambient monitoring stations within
Jefferson County, KY. PM2.5 values were assigned by zip codes of the Healthy Heart
Study participants. The PM2.5 monitor closest to the residential zip code was assigned to
each participant. The hourly levels were averaged over 1 day prior to the sample
collection.
Statistical Analysis
Independent samples t-tests (for normally distributed continuous variables),
Wilcoxon methods (for non-normal continuous variables) and chi-square analysis (for
categorical or dichotomous variables) were used to test for differences in the
dichotomized version of the distance to a major roadway variable among gender,
ethnicity, smoking status, CVD risk, CVD history, age, and median household income
within the study population.
Initially, independent sample t-test techniques were used to test for bivariate
associations between the dichotomized version of distance to roadway and VPC levels,
markers of thrombosis (platelet mononuclear cell aggregates and fibrinogen), markers of
inflammation (hsCRP), the sum of risk factors (age ≥ 40 years, male gender,
hypertension, hyperlipidemia, diabetes, and current smoking), and the Framingham Risk
Score (FRS). VPCs were log-transformed * 1000 for normality in the t-test analysis, and
the significance is reported. The mean cell levels, normalized to sample volume, are
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presented in the results, consistent with the literature. The factors that were significantly
associated with distance to roadway in the bivariate analysis were entered into the
adjusted regression model below.
Generalized Linear Modeling (GLM) techniques were used to examine whether
the VPC values were associated with distance to a major roadway, adjusting for age,
gender, body mass index (BMI), cigarette smoking, median household income (SES), and
24-hour average PM2.5. Only the population with a residential duration of at least 6
months was included in the final analysis to control for exposure misclassification. GLM
models that assessed VPCs as the dependent variable utilized the gamma probability
distribution and the log link function. GLMs that assessed the sum of risk factors utilized
the normal probability distribution and the identity link function. Traditional model-fit
statistics (log-likelihood) were used to develop the most parsimonious model. In addition
we tested whether higher order modeling (e.g., exponential, cubic) improved model-fit
using traditional model-fit statistics (AIC, log-likelihood, etc.).
Results
Participant Characteristics
The sample population was middle-aged (51±10 years old), majority male
(n=110, 54.2%), Caucasian (n=106, 52.2%) and was either a current smoker (n=78,
38.8%) or former smoker (n=67, 33.2%). A majority of the sample population had
hypertension (n=162, 81.4%); hyperlipidemia (n=126, 63.6%); were obese (BMI ≥ 30,
n=118, 59.6%); and using angiotensin-converting-enzyme (ACE) inhibitors (n=111,
55.5%), beta-blockers (n=127, 63.5%), and statins (n=101, 50.5%) (Table 13). We
successfully geocoded n=203, 84.6% of the patient addresses.
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Participant Characteristics of the Population with a Residential Proximity of 6
Months
The non-smoking sample population was middle-aged (52 years old), a majority
male (n=57, 57%), Caucasian (n=53, 53.0%) and was either a current smoker (n=38,
38%) or former smoker (n=37, 37%). A majority of the sample population had
hypertension (n=84, 84.8%); hyperlipidemia (n=66, 68%); were obese (BMI ≥ 30, n=61,
62.9%); and using angiotensin-converting-enzyme (ACE) inhibitors (n=57, 57.6%), betablockers (n=72, 72.7%), and statins (n=61, 61.6%) (Table 14). Patients with cancer were
excluded from the analysis (n=6).
Geographic Distribution
The geographic distribution of Healthy Heart Study participants in Jefferson
County. KY is shown in Figure 8. The patients are largely concentrated in the
northwestern region of Jefferson County known as West Louisville. It is also well known
that this area suffers disproportionately from cardiovascular disease and air pollution
exposure.
Demographic Comparison
Differences between the characteristics of the population living within 50m of a
major roadway were compared to people living more than 50m from a major roadway are
shown in Table 13. There were no significant differences between distance from a major
road and the following factors: age, gender, ethnicity, hypertension, hyperlipidemia,
diabetes mellitus, obesity, environmental tobacco smoke exposure, empirical smoke
exposure (cotinine), myocardial infarction, stroke, coronary artery bypass graft (CABG)/
percutaneous coronary intervention (PCI)/ or stents, heart failure, or medication use.
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People within 50m of a major road were more likely to self-report being a current smoker
(53.8% vs. 35.2%, p=0.043) and less likely to report having never smoked (12.8% vs.
31.5%, p=0.027). People with closer roadway proximity also had significantly higher
lymphocyte counts (167,394 vs. 121,368, p=0.033) and significantly lower incomes
($23,560 vs. $32,944, p=0.002).
Demographic Comparison of the Population with a Residential Proximity of 6
Months
Differences between the characteristics of the population that lived within 50m of
a major roadway were compared to people that lived more than 50m from a major
roadway are shown in Table 14. People within 50m of a major road were more likely to
self-report being a current smoker (71.4% vs. 32.6%, p=0.008), less likely to report
having never smoked (0.0% vs.29.1%, p=0.019), and more likely to have a higher mean
cotinine (1,059 ±1,136.vs. 456 ± 870 ng/mL, p=0.037). Heart failure patients were
significantly less likely to live near a major road (0.0% vs. 24.4%, p=0.037). People that
lived in close proximity to a major road also had significantly lower incomes ($23,595 ±
$6,900 vs. $34,457 ± $19,277, p=0.040).
Association between VPCs and CVD Risk with Distance to Roadway
Results of the independent-sample t-test comparison between dichotomized
distance to roadway and VPC levels, markers of thrombosis (platelet mononuclear cell
aggregates and fibrinogen), markers of inflammation (hsCRP), and CVD risk scores are
shown in Table 15. VPC-4 ((CD31+/34+/45+/AC133+); p=0.047), VPC-5
((CD31+/AC133+), p=0.007), VPC-11 ((AC133+), p=0.013), and VPC-14
((CD34+/45+/AC133+), p=0.030) were significantly associated with distance to roadway;
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these VPC levels were higher in the population that lived closer to a major roadway. The
sum of CVD risk factors was inversely associated with residential proximity to roadway
(p=0.017).
Association between VPCs and CVD Risk with Distance to Roadway in the
Population with a Residential Proximity of 6 Months
Results of the independent-sample t-test comparison between dichotomized
distance to roadway and VPC levels, markers of thrombosis (platelet mononuclear cell
aggregates and fibrinogen), markers of inflammation (hsCRP), and CVD risk scores are
shown in Table 16. There was no significant association between distance to roadway and
VPC levels, thrombosis, inflammation, or CVD risk in the population with a 6 month
residential duration.
Adjusted Association of VPCs and Distance to Roadway for the Total Population
The adjusted GLM results of VPCs and distance to roadway are shown in Table
17. The associations were adjusted for age, gender, BMI, cigarette smoking, median
household income, and 24-hour PM2.5. VPC-5 ((CD31+/AC133+), β=-0.648, p=0.003),
VPC-11((AC133+), β=-0.469, p=0.033), and VPC-14 ((CD34+/45+/AC133+), β=-1.138,
p=0.018) were significantly associated with distance to roadway. VPC levels in these
populations were higher in the population that lived closer to a major roadway, as
inferred from a negative regression coefficient. VPC-4 ((CD31+/34+/45+/AC133+), β=0.611, p=0.083) was not significantly associated with distance to roadway. The sum of
CVD risk factors was inversely associated with residential proximity to roadway (β=0.517, p=0.021), after adjustment for BMI, median household income, and 24-hour PM2.5
(not age, gender, smoking which are risk factors themselves).
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Adjusted Association of VPCs and Distance to Roadway in the Population with a
Residential Proximity of 6 Months
As previously described, only the population with a residential duration of at least
6 months was included in the final analysis. The adjusted GLM results of VPCs and
distance to roadway among individuals who resided in their homes for at least 6 months
are shown in Table 18. The associations were adjusted for age, gender, BMI, cigarette
smoking, median household income, and 24-hour PM2.5. Patients with cancer were
excluded from the analysis. Among the population with a residential duration of at least 6
months (n=80), VPC-4 ((CD31+/34+/45+/AC133+), β=-1.333, p=0.005), VPC-5
((CD31+/AC133+), β=-0.835, p=0.015), and VPC-14 ((CD34+/45+/AC133+), β=-1.037,
p=0.015) remained significantly associated with distance to roadway. VPC levels in these
populations were higher in the population that lived closer to a major roadway. VPC11((AC133+), β=-0.588, p=0.130), and the sum of CVD risk factors (β=-0.687, p=0.070
(only adjusted for BMI, median household income, and 24-hour PM2.5 (not adjusted for
age, gender, smoking which are risk factors themselves))) were no longer significantly
associated with distance to roadway when stratifying by residential duration of at least 6
months. These results held consistent when the model was adjusted for residential
duration as a continuous variable, residential duration was entered as a dichotomous
variable for 1 year residency, or stratified to include only the population with a residential
duration of 1 year or more.
Discussion
Multiple investigators have reported inverse associations between residential
proximity to roadways and CVD risk. However, the association between residential
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proximity to a major roadway and VPC levels has not been investigated. Among a panel
of 15 antigenically defined VPCs, we found that VPC-4 (CD31+/34+/45+/AC133+), VPC5 (CD31+/AC133+), VPC-11(AC133+), VPC-14(CD34+/45+/AC133+), and the sum of
CVD risk factors were significantly higher in the population living in close proximity to a
major roadway. In the adjusted analysis of the population with 6-month residency at their
current home, VPC-4, VPC-5, and VPC-14 remained significantly higher in the
population residing closer to the roadway.
The results of the current study demonstrated that individuals that lived closer to
the roadway had a higher number of CVD risk factors. This is consistent with previous
studies which determined that individuals in close residential proximity to major roads
have higher CVD risk 37, 38, 106-108. Moreover, the aforementioned result remained after
adjustment for PM2.5, but not after stratification for 6 month residential duration. This
suggests that CVD risk is associated with roadway proximity, independent of PM2.5 level.
These results regarding VPC increases with decreased road proximity are
biologically plausible. It has been demonstrated that inhalation of PM2.5 may cause
pulmonary oxidative stress and inflammation, autonomic nervous system imbalance, and
hemodynamic imbalances 32, 118. Each of these pathways causes vascular outcomes that
may result in mobilization of early progenitors (following acute exposure) or possibly
depletion of VPCs after prolonged exposure. Our findings suggest that the associations
with distance to roadway and VPCs are mostly seen in cells that are AC133+, the early
stem marker. This could indicate that with a population at risk for CVD, living closer to
the roadway leads to mobilization of early VPCs, possibly as a protective mechanism
against environmental insults.
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VPC levels increase following a vascular insult. They are mobilized into
circulation to the site of injury to achieve their role in vascular repair. Faidini et al.
described that as atherosclerosis progresses to an event in low risk populations, VPCs are
mobilized into circulation, but this action can be limited in high risk populations where
VPCs have been depleted 80. Furthermore, as the number of risk factors increase, it is
more likely that individuals are being treated for primary prevention of CVD through
statins which increase VPC levels 64, 81, 87, 88 and VPC mobilization.89-91.
Although we determined that VPC levels are significantly increased in the
population living in closer proximity to a major roadway, the adjusted regression model
did find that PM2.5 was inversely associated with VPC levels in the population with 6
month residency (cancer patients excluded), adjusted for age, gender, smoking, BMI,
SES, and distance to a major roadway. VPC-5 (β=-0.048, p=0.009), VPC-11 (β=-0.063,
p=0.003), VPC-14 (β=-0.062, p=0.047) were inversely associated with PM2.5. O’Toole et
al. also determined that VPC levels were inversely associated with PM2.5 exposure during
temperature inversions in Provo, UT 30. While the current population was relatively
unhealthy in terms of CVD risk, the population in the study by O’Toole et al. was
comprised of healthy collegiate athletes. The current study demonstrated VPC decreases
associated just as the O’Toole et al. investigation. However, the current study was able to
determine this with lower PM2.5 exposure levels. This suggests that even at lower PM2.5
exposure levels, there are still detectable VPC reductions.
Among the strengths of our study include the large study population. The range of
CVD risk factors within our study population make it a diverse group to study.
Additionally, our study includes multiple phenotypically distinct VPC populations to
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understand which populations are associated with distance to roadway. We were able to
account for potential confounding by measuring cotinine levels, the primary urine
nicotine metabolite, in addition to collecting data on self-reported smoking. Cancer
patients were excluded from the final analysis because VPCs are recruited in tumor
angiogenesis 75-77, which may increase VPC levels (we did not find significantly different
associations when including or excluding cancer patients in the final analysis). Including
the residential duration in our sub-analysis allowed additional benefit in our
understanding of VPC associations with road proximity because it allowed for reduced
exposure misclassification in the population that had not resided at their homes for a
long-term duration.
One important limitation includes not accounting for some potential confounders
in traffic exposure, including traffic noise, which has been associated with higher blood
pressure 119 and increased risk of adverse cardiovascular outcomes 120, 121. It is also
associated with distance to roadway; therefore, it is an important factor to consider in
roadway proximity studies. Additionally, land use and tree cover, factors that can mediate
or exacerbate traffic pollution exposure, were also not accounted for in the current study.
Moreover, PM2.5 exposures were assigned by zip code, rather than inverse distance
weighting or other interpolation methods. The use of road proximity as an indicator of
exposure to traffic pollutants assumes that study participants spend much of their time at
home. Therefore, it does not account for the duration of time individuals spend outside
their home and road proximity during other activities. There was also no account for time
spent in vehicles or participation in traffic, which has been associated with increased
cardiovascular risk 35. Socioeconomic status (SES) is an important consideration in
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cardiovascular research because of its association with adverse cardiovascular risk. The
foremost measure of SES is maternal education, which was not assessed in the study
questionnaire. We assessed median household income for the Census block group of the
participant’s residential address to approximate SES. The duration of home ownership
was helpful to account for exposure misclassification; however, we were unable to
account for the population that rents property because that variable was not included in
our study questionnaire. Additional limitations include the study design: a cross-sectional
analysis of a convenience sample recruited from cardiology clinics. Therefore, the
findings represent the CVD risk population in Louisville, KY and cannot be extrapolated
to represent the general population, even in Louisville, KY.
Future directions from this research should involve the inclusion of a CVD-free
control population. More detailed information on residential address history and duration
would be helpful to define exposures and inclusion of multiple study sites would be
beneficial in understanding the differences between roads with higher or lower mean
annual vehicles. Additionally, research into the mechanism by which traffic pollution
exposure influences circulating VPC levels is needed. Determining which component of
vehicular traffic pollution influences circulating VPC levels might also broaden our
understanding of how the environment contributes to CVD.
Conclusions
The sum of CVD risk factors along with VPC-4 (CD31+/34+/45+/AC133+), VPC-5
(CD31+/AC133+), VPC-11(AC133+), and VPC-14(CD34+/45+/AC133+) were elevated in
the population that resided in closer proximity to the roadway. VPCs with the AC133+
phenotype were higher in people who lived closer to a major road, suggesting that the
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effects of traffic pollutants on the vascular system may be associated with increased
circulation of AC133+ cells as a means of vasoprotection. The finding that the population
in closer proximity to the road has higher levels of early progenitors is intriguing given
our finding that CVD risk decreases with increased roadway distance. This suggests that
the population living in close proximity to the road has higher risk and this may have
stimulated VPCs into circulation. This is biologically plausible because increased risk
alone may stimulate VPCs into circulation.
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Figures and Tables

Figure 8. Patients’ residential locations in Jefferson County, KY.
Patient addresses are geographically masked.
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Table 13. Demographics and CVD risk history stratified by roadway proximity.
Current, never, and former smokers are based on self-report. Environmental smoke is
self-reported secondhand smoke exposure in non-smokers only. BMI = body mass index.
Cotinine units (ng/mL). CABG = coronary artery bypass graft. PCI = percutaneous
coronary intervention. ACE = angiotensin-converting-enzyme. Vasodilators include
nitrates and hydralazine. Median household income in USD at the US Census block
group level. ** = significant at the 0.05 level.
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Table 14. Demographics and CVD risk history stratified by roadway proximity in
people with a residential duration of 6 months.
Cancer patients (n=6) were excluded from this analysis. Current, never, and former
smokers are based on self-report. Environmental smoke is self-reported secondhand
smoke exposure in non-smokers only. BMI = body mass index. Cotinine units (ng/mL).
CABG = coronary artery bypass graft. PCI = percutaneous coronary intervention. ACE =
angiotensin-converting-enzyme. Vasodilators include nitrates and hydralazine. Median
household income in USD at the US Census block group level. ** = significant at the
0.05 level.
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Table 15. Comparison of VPC levels, thrombosis, inflammation, and CVD risk
between roadway proximities.
VPC counts per µL sample. Fibrinogen units (mg/dL). Platelet mononuclear cell
aggregates are the percent of total cells CD41+/45+. HsCRP units (mg/L). The sum of
CVD risk factors includes the following Framingham risk factors: age ≥ 40 years, male
gender, current smoker, hypertension, hyperlipidemia, and diabetes. ** = significant at
the 0.05 level.
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Table 16. Comparison of VPC levels, thrombosis, inflammation, and CVD risk
between roadway proximities in people with a residential duration of at least 6
months.
Cancer patients (n=6) were excluded from analysis. VPC counts per µL sample.
Fibrinogen units (mg/dL). Platelet mononuclear cell aggregates are the percent of total
cells CD41+/45+. HsCRP units (mg/L). The sum of CVD risk factors includes the
following Framingham risk factors: age ≥ 40 years, male gender, current smoker,
hypertension, hyperlipidemia, and diabetes. ** = significant at the 0.05 level.
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Table 17. Association between roadway proximity, VPC levels, and CVD risk.
Samples were adjusted for age, gender, BMI, cigarette smoking, median household
income, and 24-hour PM2.5. GLMs that assessed VPCs as the dependent variable utilized
the gamma probability distribution and the log link function. GLMs that assessed the sum
of risk factors utilized the normal probability distribution and the identity link function.

Table 18. Association between roadway proximity and VPC levels in people with a
residential duration of at least 6 months.
Samples were adjusted for age, gender, BMI, cigarette smoking, median household
income, and 24-hour PM2.5. GLMs that assessed VPCs as the dependent variable utilized
the gamma probability distribution and the log link function. Cancer patients (n=6) were
excluded from this analysis.
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OVERALL DISCUSSION
Highlights
These chapters describe how VPC levels are associated with CVD risk and
environmental pollution exposure. In the first chapter, it was determined that VPC levels
are associated with increased CVD risk, possibly through recruitment in thrombosis and
suppression in inflammation. Previous investigators reported mixed results in describing
the associations between risk and VPC levels. Because VPCs are a heterogeneous
population containing cells of different angiogenic potential, investigation of the large
panel of VPCs in the current study more accurately described which VPCs subpopulations are associated with increased CVD risk in an at-risk population. In the
second chapter, it was described that the acrolein metabolite, HPMA, was associated with
reduced VPC levels: suggesting that exposure to acrolein is associated with decreased
VPCs. Additionally, HPMA was associated with increased thrombosis and increased
FRS. The associations between acrolein exposure and VPC levels and thrombosis had
been demonstrated in mice, but not in humans. In the final chapter, individuals who lived
closer to a major roadway had a higher number of risk factors for CVD and higher VPC
levels. This was a novel assessment in the field and the findings suggest that VPC levels
are increased as a means of vasoprotection in either roadway exposure or increased CVD
risk, or both. Ultimately, these investigations revealed that environmental pollution
exposure is associated with VPC levels, which may also contribute to CVD risk.
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Strengths
Population size

There are multiple strengths of these investigations. First, there was a large
population recruited for this study, ranking us among the largest VPC investigations of
at-risk individuals. Many investigations of VPCs and CVD risk have investigated
associations in less than 100 people 52, 63, 65, 67, 69-72, 122, 123. Most of these investigations
utilized a case-control design. The current study utilized a cross-sectional design, which
requires more study participants for more strength of association. Werner et al.
investigated a large population (n=507) using a prospective cohort 74. Kunz et al.
investigated a cross-section of 122 patients undergoing diagnostic cardiac catheterization
66

. Xiao et al. investigated a cross-section of 574 low-risk individuals 64. The current

study includes a population of 240 individuals (189 with VPC levels) with risk factors for
CVD. The current study was statistically powered to detect associations with VPC levels.
With an effect size of 20%, 10 predictors, and statistical significance of 0.05, there is a
1% chance that our conclusion that VPC levels are associated with CVD risk factors and
environmental exposures is invalid and they are actually not associated.
Susceptible population
Previous research of vascular progenitor cells and the association with CVD risk
have included both healthy and unhealthy individuals, in terms of CVD risk. The
environmental investigation of VPCs and risk, however, investigated VPC levels in
healthy young adults 30. It is important to add to the literature an investigation of
susceptible individuals and their VPC levels associated with environmental exposures.
Older individuals are more susceptible to the effects of environmental exposures. In
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addition, older individuals are more likely to have heart disease. Moreover, patients with
heart disease may be more susceptible to the effects of environmental exposures 38.
Investigating a susceptible population that includes both older individuals and a
population who have heart disease allows for greater understanding of cardiovascular
risks of environmental exposures, determined through VPC levels.
Antigenic markers
The current study used antigenic markers CD31+, CD34+, CD45+/dim, and
CD133+/– to define VPCs. These markers are useful in defining circulating VPCs. Some
previous investigations used markers which were not highly specific to VPCs, including
1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate labeled acetylated
low-density lipoprotein (DiI-Ac-LDL) and lectin. In addition to using validated antigenic
markers, the current study also verified that selected populations were positive for the
transcription factor inhibitor of DNA binding 1, Id1, indicating that they are endothelial
progenitor cells.
VPC measurement
Some previous studies investigated VPCs using culture and colony forming unit
assays. These assays are beneficial in determining the growth and functional capacity of
VPCs 64, 65, however, they are less suitable in determining levels of circulating VPCs. The
current study quantifies VPCs using flow cytometry, a superior method for circulating
VPC identification and quantification. Additionally, flow cytometry allows for multiple
measurements with rapid speed. This methodology is beneficial for future clinical use of
VPC quantification. If a proper cell type is identified to be useful in detection of CVD,
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the clinical staff will be able to have flow cytometry results, using the current study’s
methodology, within hours.
VPC population specificity
VPCs are a heterogeneous population of cells with different angiogenic potential.
The current study measured 15 antigenically distinct populations of VPCs. Results from
this investigation have scientific significance because of the determination of specific cell
types and sub-populations that are associated with CVD risk and environmental
exposures. O’Toole et al. determined that CD31+/34+/45+ cells are inversely associated
with PM2.5 exposure

30

. The current study also determined that CD31+/34+/45+ cells were

inversely associated with HPMA, but the results also demonstrated that a sub-population
of those cells were also inversely associated, CD31+/34+/45+/AC133–: suggesting that
depletion of the late progenitor (AC133–), rather than the more immature progenitor cell
population (AC133+), drives the association demonstrated in CD31+/34+/45+ cells. By
assessing a large number of VPCs, in some cases a more specific marker population that
is affected can be determined. This is beneficial for future mechanistic investigations,
allowing for future investigations to be targeted at more specific cell types, and for
greater understanding of which cell differentiation state is influenced by pollution
exposure and CVD risk.
Minimizing exposure misclassification

To reduce exposure misclassification, multiple efforts were employed including
the use of biomarkers. Measuring urine HPMA concentrations allows for a reliable
measure of individual acrolein exposure. Estimating acrolein exposure using ambient
monitoring would not provide as much benefit if used instead of metabolism
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quantification because estimates would be more specific to a community rather than an
individual and the difficulties in determining the amount of time individuals are exposed.
HPMA is the primary urine metabolite of acrolein, and it is specific to acrolein exposure
46

, making it the most reliable marker to quantify acrolein exposure. With this

measurement, the current study was able to determine the HPMA levels of a person at the
timing that coincides with the timing of the individual’s VPC and cotinine levels. This
way, the snapshot of exposures occurs at the same time of the outcome measure, VPCs.
Cotinine was also a biomarker utilized in the current study to reduce exposure
misclassification in self-reported smoking. Additionally, cotinine is a continuous variable
that allows quantification of the exposure to tobacco smoke. It accounts for both primary
and environmental exposure to tobacco smoke.
Exposure misclassification in the association between VPCs and distance to a
major roadway was minimized through including only individuals who had a residential
duration at their current home of at least 6 months. This reduced attributing long-term
exposures to persons with short-term residency.
Limitations
Convenience sample
The results of the current study are valuable because they add knowledge about
the association of environmental exposures with VPC levels, which may contribute to
CVD risk. These associations were determined in a population with increased risk factors
for CVD, which poses a limitation in being able to generalize the results to the whole
population. Each participant was recruited during cardiology clinic visits, therefore, their
clinic visit was related to cardiology concerns. This implies that the population has poor
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cardiovascular health. Additionally, when reviewing our population characteristics,
24.6% (n=59) of the study population were primary preventive patients, and 75.4%
(n=181) were secondary preventive patients, indicating that 75% of the participants had
overt CAD. For these results to be generalizable beyond a high-CVD risk population,
more people who are low-risk must be included in the population. A comparison
population with 1 or less risk factors would be ideal to include for understanding the
differences between VPC levels among risk scores and risk factors. Future direction
should include age- and sex-matched controls with no additional risk factors (outside of
age and gender).
Recruitment
In addition to the convenience sample from the cardiology clinics posing a
possible limitation, recruiting a sample population that is representative of the clinic
patient demographics may be another limitation. The population of the current study may
not entirely represent the clinic population demographics. For example, none of the
recruiters for the current study fluently spoke any languages other than English;
therefore, participants who were not English-speaking and did not have a translator
present could not participate in the study. Possibly as a result, only 1.7% (n=4)
individuals in the current study were Hispanic.
It is estimated that 75% of the individuals that were recruited enrolled in the
study. Many of those that did not enroll explained that they had time limitations, were
uncomfortable with the biological sample collection, or were not interested. At the onset
of the study, limitations included retaining study participants after the questionnaire
administration to provide biological samples following their appointment. Initially, the
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recruiters would ask patients to meet them at the phlebotomy lab immediately following
their appointment for biological sample collection. This had poor retention outcomes
because some patients were unable to locate the lab, some may have forgotten, and some
may have changed their minds about providing samples. The current study was able to
change this trend by increasing the number of recruitment personnel and assigning
recruiters to specific patients and escorting them to the lab to provide samples. An
additional challenge involved individuals that had “rolling” veins or veins that were
difficult to locate. In these scenarios, multiple sticks may have been required for an
adequate blood draw, adding to the patient’s discomfort.
Misclassification
Measuring cotinine levels to minimize exposure misclassification in tobacco
smoke exposure provided a strength in the study by allowing for quantification of smoke
exposure. Ironically, it also provided as an additional means for exposure
misclassification. In some assessments, smoke exposure was associated with an outcome,
but cotinine was not: although self-reported smoking and cotinine were highly correlated.
If, for example, a study participant reported that they were a smoker, but had not had a
cigarette in 20 hours, their cotinine levels may represent a non-smoker’s cotinine level.
Assessing only the population with a residential duration of at least 6 months was
a great step toward reducing exposure misclassification. Narrowing the population to the
individuals with at least 6 month home ownership, however, may have misclassified
renters in the study population. If a renter has been in their current home for more than 6
months, but the property owner changed less than 6 months prior, they would have been
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misclassified. If, on the other hand, renters had recently moved to the property, but the
owner had not changed, their exposure measurement would also be misclassified.
Determining whether or not an individual was a smoker may have possibly led to
misclassification. Some study participants indicated that they were current nonsmokers,
but had only quit smoking weeks prior to the questionnaire. Additionally, some
individuals described themselves as current smokers, but only smoked a few cigarettes a
week or just socially. Some investigations only consider individuals to be nonsmokers if
they have abstained for 6 months. Because of the difficulties in quantifying exposure, we
also measured cotinine levels. The difficulty in quantifying smoke exposure is similar to
other variables in the current dataset including alcohol consumption and exercise. Instead
of quantifying the amount of exercise or alcohol, these variables were entered as
dichotomous data, possibly leaving heavy consumers of alcohol in the same category as
individuals who consume infrequently.
Outcome measurement
Some patients were not able to provide blood samples that were needed to
measure VPCs. Patients that had engaged in past intravenous drug use that caused their
veins to be damaged (or others that were not able to provide samples from their arm)
occasionally provided blood samples from their hands, which may have resulted in
slower blood flow into the vacutainer tubes. The cell preparation tube (CPT) separator
vacutainer required 8 mL of blood for VPC measurement; some patients were not able to
provide this amount, possibly resulting in cell levels that were too low to be counted by
the flow cytometer.
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There is potential bias in the measurement of VPCs. Although the operator was
blinded to the disease status and risk factors of the patient, it could have been assumed
that most study participants are diseased because of their recruitment from cardiology
clinics. This may have influenced the flow cytometric interpretation through operator
bias. Additionally, the gating of cell properties in flow cytometry can appear somewhat
arbitrary and possibly differ from investigator to investigator. Therefore, one investigator
directed and verified the gating for consistency. Additionally, the CD31+ antigenic
marker is considered to be less specific in indicating the endothelial phenotype than the
kinase insert domain receptor (KDR+) (vascular endothelial growth factor receptor-2+
(VEGFR-2+) is also known as KDR+). To address not marking for KDR+ rather than
CD31+, we verified the endothelial progenitor cell phenotype with the presence of Id1+
cells that were CD31+.
VPCs are useful to investigate because they are specific to the vascular and
cardiovascular systems and are sensitive to environmental exposures. It is important to
control for many factors in human VPC assessments because many factors influence
levels of circulating VPCs. Gender influences VPC levels; VPC levels fluctuate during
the menstrual cycle in women. A study limitation is that the current investigation did not
account for what phase of menstruation female participants were undergoing. To account
for this, the current study stratified by gender to determine whether associations changed,
and the direction of associations did not change. Additionally, differences were compared
between VPC levels among genders, and no significant differences were found between
VPC levels and gender. Models in the current study were adjusted for gender to account
for any undetermined differences between men and women (except models with FRS or
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FRS category because gender is weighted in the risk score). Additionally, exercise
influences VPC levels by mobilizing VPCs from the bone marrow into circulation. The
questionnaire item for exercise was not robust enough to adequately quantify exercise
within the study population. Adjusting the models for exercise did not appear to provide
additional benefit over adjusting for BMI, in terms of statistical significance. Therefore,
BMI (a continuous variable) was entered into the selected adjusted regression models.
BMI provides an additional limitation in that it has been reported that waist
circumference and waist-to-hip ratio are more closely related to adverse cardiovascular
health 124, 125.
An additional limitation in the outcome measurement is the lack of adjusting our
analyses for multiple comparisons. Associations between each VPC and the exposure and
risk factor were assessed individually, one model for each VPC – 15 total. The current
study investigated each cell separately to understand the associations between each VPC
and the exposures and risk factors individually. If there is a 5% chance of error for each
model, this increases the likelihood that there will be an association determined within 15
models that is erroneous.
CVD risk/ exposure measurement
A crude measure of risk included in our assessments was the “sum of CVD risk
factors” variable. This variable allowed for greater understanding of how increases in
cumulative risk factors are associated with VPC levels. This measure is less valid to
assessing risk because it does not weight for different risk factors. Ultimately, CVD risk
is predicted by the FRS and FRS category in the current study. The FRS predicts future
myocardial infarction and cardiac mortality. Some criticism of the FRS is due to the
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original study cohort being unrepresentative of the general population: completely
Caucasian and middle class. The Framingham Heart Study now includes multiple
ethnicities in its subsequent cohorts 126, and the FRS has been validated against other
ethnicities 127. Additional criticism of the FRS involves the lack of accurate prediction for
women and individuals in the intermediate risk category (FRS 10 – 20) 22. This poses a
limitation where women and individuals with intermediate risk may not have an
appropriate risk score. In fact, cardiovascular events can occur without an individual
having any Framingham risk factors. The Reynolds Risk Score (RRS) is another risk
algorithm predicting risk of adverse cardiovascular outcomes. The RRS predicts heart
attack, stroke, coronary revascularization, and cardiovascular death. It was derived to
better estimate risk in women and intermediate risk populations. The RRS includes
Framingham risk factors (age, hypertension, hyperlipidemia, diabetes, smoking, and
gender) along with family history and C-reactive protein (CRP). The current study was
unable to investigate the RRS due to incomplete family history data. Investigating risk in
terms of the RRS in its association with VPC levels will be a beneficial and novel
approach in future assessments. Because the current investigation determined that VPC
levels were inversely associated with hsCRP in an at-risk population, it would be
interesting to understand the association with the RRS. Ultimately, the RRS may be a
better predictor of VPCs suppressed in inflammation, while the FRS may better predict
VPCs recruited in thrombosis. More research would be required to investigate the
potential associations.
Additional cardiovascular risk scores that may provide added benefit in
understanding the association between VPCs and risk include the Systematic COronary
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Risk Evaluation (SCORE), which measures the risk of fatal CVD with an algorithm
including age, gender, total cholesterol, systolic blood pressure, and smoking 128. The
Prospective Cardiovascular Münster (PROCAM) Study score assesses risk of myocardial
infarction and cardiac death through an algorithm that includes age, low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, smoking,
systolic blood pressure, family history, diabetes, and triglycerides 129. The DiamondForrester score predicts significant CAD through age, sex, and chest pain 130. Because
these scores measure different outcomes, their association with VPC levels may be
helpful for greater understanding of the role of these cells in CVD risk.
HPMA is a marker of acrolein metabolism, but it is not possible to attribute the
acrolein exposure only to the environment. There are environmental sources of acrolein
exposure (combustion of fossil fuels, open fire, industrial emissions, vehicular exhaust,
and tobacco smoke), but there is also endogenous acrolein exposure as well as exposure
to acrolein in food and alcohol consumption. It is not known what portion of our acrolein
exposures are endogenous compared to environmental. Therefore, to better estimate
environmental acrolein exposure, in addition to HPMA levels, it would have also been
beneficial to have ambient acrolein levels as well. Personal samplers would be best
because they would remain with a person wherever their daily activities lead them.
However, these additionally provide limitations because individuals may not wear them
properly or wear them at all. Some find these uncomfortable, and they are an added
expense for the investigator. In-home monitors would also be beneficial, but that may not
be where the participants spend most of their time. There are also complaints of the noise
and space they impose. Ambient air monitoring stations throughout the study area would
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be beneficial, but there are not enough acrolein monitors distributed widely across
Jefferson County, KY to provide a valid estimation of such a volatile chemical.
Roadway proximity studies operate with the assumption that study participants
spend a majority of their time at home. A better estimation would involve geocoding the
distance to roadway of both the home and work addresses and accounting for the time
spent at both. Additionally, inclusion of a variable that accounts for efficiency and
insulation in homes, possibly estimated by the age of the home, would provide benefit in
attributing exposures.
Future Directions
Because of the multiple implications of examining whether a population with
increased CVD risk has vascular progenitor cell levels that are associated with CVD risk
and environmental exposures, there are many directions in which the current study results
can be expanded and applied. The results of the current study should be assessed in
animal models. Mechanistic explorations in animals will add greater understanding of the
associations between the environment and CVD risk, detected by VPC levels.
One key goal is to determine the best VPC population to be measured in a clinical
setting for diagnostic purposes in CVD. As described before, VPC levels can be
quantified within hours, allowing for a quick turn-around on information. Future
investigations should determine whether VPC levels provide additional benefit to
determining risk in the population within the intermediate FRS category (FRS 10 – 20).
Understanding which VPC populations are associated with specific risk factors will be
helpful in determining targets for therapeutic interventions. Determining, for example,
the VPC population associated with hypertension will allow for future investigations that
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mobilize these VPCs in hypertensive patients. In the current study, VPC levels are
suppressed in patients with inflammation. Future investigation of mechanistic means to
increase VPC-5 (CD31+/AC133+) in patients with inflammation may minimize or prevent
vascular damage, improving patient cardiovascular outcomes.
In an effort to determine populations that are most associated with risk, we
divided the cell populations into groupings based on the single antigenic markers and
possible sub-populations. Possibly because there is much overlap between the cell
populations and many are correlated with each other, we did not find trends in
associations on this basis (with the exception of VPCs and proximity to a major
roadway). Future directions should consider the antigenic marker similarities common to
the risk factor or exposures and develop hypotheses on that basis to guide future
understanding.
Because it has now been determined that VPCs decrease in humans exposed to acrolein,
understanding the mechanism of VPC depletion in animals will give better understanding
of the role of acrolein exposure in vascular damage. Because the population living closer
to the roadway had a higher number of risk factors and higher number of VPCs, future
investigations should explore whether the VPCs are increased in the population living
closer to the road because increased CVD risk results in these cells being mobilized into
circulation, environmental insults are stimulating VPC mobilization, or both.
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OVERALL SUMMARY
Taken together, these chapters describe how environmental pollution exposure is
associated with VPC levels, contributing to CVD risk. In the first chapter, the objective
was to describe the associations between VPC levels and cardiovascular disease risk.
VPCs in circulation are suspected to be a sensitive indicator of cardiovascular health.
Several investigators have suggested that circulating VPC levels are decreased in
populations with CVD; however, some positive associations with CVD have been
demonstrated. Likely reasons for the mixed results may be due to the use of cellular
definitions that were non-specific to VPCs and assays not specific to quantifying
circulating levels of these cells. Therefore, the current study evaluated the relationship
between CVD risk and VPC levels using antigentically defined VPCs with angiogenic
potential. CVD history and risk factors, blood, and urine were collected in a crosssectional assessment of 240 patients in the Louisville, KY Healthy Heart Study receiving
primary or secondary preventive treatment for CVD. Fifteen VPC populations measured
in peripheral blood using VPC-specific antigenic markers of CD31+ (endothelial cell),
CD34+ (stem cell), CD45+/dim (hematopoietic/ non-hematopoietic), AC133+/– (early/ late
progenitor cell) were quantified using flow cytometry. Generalized Linear Modeling
(GLM) techniques were utilized to describe associations between VPC levels, traditional
CVD risk factors, the Framingham Risk Score (FRS), plasma levels of fibrinogen, and
platelet mononuclear cell aggregates in whole blood (markers of thrombosis), and serum
levels of high sensitivity C-reactive protein (hsCRP; a marker of inflammation). FRS
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category was inversely associated with VPC-5 (CD31+/AC133+) and positively
associated with VPC-3 (CD31+/34+/45dim/AC133+), VPC-13 (CD34+/AC133+), and VPC15 (CD34+/45dim/AC133+). Fibrinogen was positively associated with VPC-1
(CD31+/34+/45dim), VPC-3, VPC-13, and VPC-15. Platelet mononuclear cell aggregates
were positively associated with VPC-6 (CD31+/34+), VPC-9 (CD34+), and VPC-14
(CD34+/45+/AC133+). HsCRP was inversely associated with VPC-5 and VPC-11
(AC133+) levels. These results suggest that VPC-5 levels decrease as risk increases,
possibly through suppression during inflammation. Results also indicate that VPC-3,
VPC-13, and VPC-15 increase as risk increases, possibly due to their role in resolving
venous thrombus. Results from this investigation described how VPC levels are
associated with CVD risk in a population at increased risk for CVD. Future direction
from the current investigation should involve the verification of these results in animal
models to understand the mechanism behind these associations. Additionally, future
planned research will investigate these associations beyond an at-risk population.
In the second chapter, the association between acrolein exposure and VPC levels
was assessed to understand how the environment contributes to CVD risk. Combustion
pollutants, including acrolein, are associated with decreased VPC levels in mice;
however, this was the first investigation of the association between acrolein exposure and
VPC levels in humans. To estimate acrolein exposure, the primary urine acrolein
metabolite HPMA was quantified using gas chromatography / mass spectrophotometric
analysis (GC/MS). Additionally, urine levels of the nicotine metabolite, cotinine, were
determined by GC/MS. The associations between HPMA concentrations and smoking,
VPC levels, the FRS, and the markers of thrombosis and inflammation were assessed
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using GLM techniques. HPMA levels were positively associated with tobacco smoke
exposure. After adjustment for traditional risk factors and potential confounders, VPC-2
(CD31+/34+/45+), VPC-8 (CD31+/34+/45+/AC133–), VPC-11, and VPC-14 were inversely
associated with HPMA. Platelet mononuclear cell aggregates were positively associated
with HPMA. The FRS and FRS category were positively associated with HPMA. VPC-2,
VPC-8, VPC-9, and VPC-14 were inversely associated with HPMA after stratification for
non-smokers. The major finding of this study is that exposure to acrolein is associated
with vascular outcomes, determined through reductions in circulating levels of VPCs.
Additionally, as acrolein exposure increases (detected by acrolein metabolism), a marker
for thrombosis (platelet mononuclear cell aggregates) and CVD risk increase.
Implications of these results are of added value because the current study found these
associations in a population with increased risk for CVD, a population more susceptible
to the effects of environmental exposures.
The third chapter presented the association between proximity to a major roadway
and VPC levels as an added analysis in understanding the environmental contribution to
VPC levels and CVD risk. A substantial body of research has established that living in
close proximity to a major roadway is associated with increased CVD morbidity and
mortality; however, this is the first investigation of the impact of exposure to traffic
pollution on VPC levels. Vehicular exhaust is a source of acrolein exposure, and distance
to roadway is a common measure of exposure to traffic-related pollution. The objective
was to investigate the association between residential proximity to a major roadway (an
indicator of traffic pollution exposure) and circulating VPC levels indicating CVD risk.
Residential addresses were geocoded in a Geographic Information System (GIS), with
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major roadways defined as roads carrying an annual mean of 5,000 or more vehicles/ day.
Individuals were considered exposed if they resided within 50m of a major roadway. The
association between roadway proximity and VPC levels, CVD risk factors, the FRS, and
markers of thrombosis and inflammation was assessed using GLM techniques, and the
models were adjusted for traditional covariates along with potential confounders. Only
the population with a residential duration of at least 6 months was included in the final
analysis. A large portion of study participants resided in the northwestern portion of
Jefferson County, KY, called, “West Louisville,” which has disproportionately high CVD
mortality rates and environmental exposures. Levels of VPC-4 (CD31+/34+/45+/AC133+),
VPC-5, and VPC-14 were significantly higher in the population in close proximity to the
roadway after adjustment for potential confounders. VPCs with the AC133+ (early
progenitor cell) marker were higher in people who lived closer to a major road,
suggesting that the effects of traffic pollutants on the vascular system result in increased
circulation of early (immature) progenitors as a means of vasoprotection. Because the
population living closer to the roadway had a higher number of risk factors and higher
VPC levels, future investigations should explore whether the VPCs are increased in the
population living closer to the road because increased CVD risk results in these cells
being mobilized into circulation, environmental insults to the vasculature are stimulating
VPC mobilization, or both.
Taken together, these chapters describe an important aspect of the influence of the
environment on CVD risk, assessed by VPC levels. The first chapter is significant
because it accurately defined VPC populations to assess potential VPC associations with
CVD risk factors in a population at increased risk for CVD. The second chapter expanded
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scientific knowledge through quantifying individual levels of the primary acrolein
metabolite to determine its association with adverse cardiovascular health in humans, a
novel investigation. The third chapter advanced the field of environmental cardiology by
evaluating the established association between roadway proximity and CVD risk through
investigation of VPC levels, a novel assessment in the field. Results of these
investigations provide insights for future mechanistic assessments of VPCs, and add
additional information to drive future investigations for VPCs in interventional therapies
for CVD risk factors and environmental exposures.
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